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Abstract
Cancer-associated deaths account for the second-highest mortality rates in the United States.
Primary modalities of treatment often include surgery, radiation, and chemotherapy, and may also
incorporate targeted therapy and immunotherapy. However, resistance to these treatments remains
high, resulting in disease reoccurrence and poor survival rates. While apoptosis or cell death of
tumor cells is the ideal outcome for anti-cancer therapy, this is often not the case, and in fact cancer
cells may upregulate several pathways, such as autophagy and senescence, as a means to undergo
alternative cell fate and evade apoptotic cell death. An essential tumor suppressor gene, TP53,
regulates all three of these processes, apoptosis, autophagy, and senescence, and loss of function
or mutated TP53 is often implicated in early tumorigenesis and reduced sensitivity to
antineoplastic therapy. To assess the effects of p53 status on the functionality of autophagy and
cellular responses to radiation and chemotherapy, we utilized a pair of isogenic non-small cell lung
cancer cells (NSCLC) expressing wild type p53 (H460wt) or lacking p53 expression generated
using CRISPR/Cas9 editing (H460crp53). Exposure to the DNA-damaging agents, cisplatin and
radiotherapy, revealed differential sensitivity between H460wt and H460crp53 cells, in which
H460crp53 cells were significantly less sensitive to cisplatin and radiation exposure compared to
their wild-type counterpart. In response to radiotherapy, apoptosis was induced to similar extents
in both cell lines, while autophagy interference identified a nonprotective function of autophagy
in response in both cell lines, regardless of p53 status. Rather, the differential radiosensitivity
exhibited between H460wt and H460crp53 cells was attributed to differences in senescence
induction, where H460wt cells demonstrated a significantly greater extent of senescence induction.
Of particular interest was the finding that when the same set of isogenic cell lines was exposed to
cisplatin, the cells exhibited a similar extent of senescence induction over time; however,

XV

autophagy inhibition revealed two different functional forms of autophagy: nonprotective
autophagy in H460wt cells and cytoprotective autophagy in H460crp53 cells. Blockade of
cytoprotective autophagy in H460crp53 exposed to cisplatin was sufficient to restore sensitivity
and apoptosis induction to a similar extent as in the H460wt cells, further confirming the existence
of an autophagic switch and the role of cytoprotective autophagy in the initial resistance to
cytotoxic therapy. Finally, given concomitant activation of both autophagy and senescence in
response to chemotherapy and radiation, we also examined the relationship between these two
processes. At least in the case of nonprotective autophagy, autophagy inhibition did not interfere
with senescence induction or proliferative recovery from growth arrest, indicating these two
processes may be dissociated when autophagy is nonprotective in function. Taken together, cancer
chemotherapy and radiotherapy activate a number of cellular mechanisms, such as autophagy and
senescence, and not solely apoptotic cell death; consequently, further analysis and screening are
warranted prior to therapeutic administration of autophagy inhibitors to patients. While autophagy
seems to be an attractive therapeutic target under its cytoprotective function, autophagy can in fact
play multiple functions and switch functional responses. These studies demonstrate that autophagy
is contextual in nature and may, in part, depend on the therapeutic modality utilized and the p53
status of the tumor cells.
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Chapter One: General Introduction
1.1 Lung Cancer
1.1.1. Lung Cancer: Overview
Lung cancer is the second most common type of cancer and is responsible for the most cancer-related
deaths in the United States, yearly (1). There are two major types of lung cancer, which are divided
histopathologically: non-small cell lung cancer (NSCLC), which accounts for ~80-85% of new cases,
and small cell lung cancer (SCLC), which contributes to ~10-15% of lung cancer cases (2). The most
common causes of lung cancer include smoking, family history, and exposure to certain
environmental factors, such as asbestos, radon, and other carcinogens (3). SCLC often starts in the
bronchi in the middle of the chest but is highly aggressive and grows rapidly, resulting in diagnosis at
later stages and poorer survival rates when compared to NSCLC (4). Furthermore, SCLC is strongly
associated with smoking (5,6). Differences between SCLC and NSCLC are usually defined by light
microscopy through hematoxylin and eosin (H&E) staining and cytology of patient biopsies. SCLC
appears as small (< the diameter of 2-3 resting lymphocytes) and round-fusiform shaped cells
compared to tumor cells in NSCLC, which appear larger (7–9). SCLC has a higher nuclear/cytoplasm
ratio, higher mitotic activity, finely granular nuclear chromatin, and nuclear molding (8,9). There are
three major subtypes of NSCLC: adenocarcinoma, squamous cell carcinoma, and large
undifferentiated cell carcinoma (10,11). Adenocarcinomas usually encompass the outer parts of the
lungs and incorporate cells that normally secrete substances, such as mucus (3). Squamous cell
carcinomas initiate from the flattened squamous epithelial cells that line the inside of the airways in
the lungs (3).
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The most common mutations in lung cancer include KRAS (30%), EGFR (up to 23%), and TP53
(50%) (12–15); moreover, tumors with p53 mutations generally have a poor prognosis and exhibit
chemoresistance (16,17). Lung cancers have a high p53 mutation rate, of approximately 46% in lung
adenocarcinoma and 81% in squamous cells; moreover, lung cancer also has a high percentage of
TP53 mutational hotspot regions (18). TP53 is an essential tumor suppressor gene coding for the
protein, p53, that plays a role in regulating a number of cellular responses, including but not limited
to apoptosis, autophagy, and senescence (19–21).

1.1.2. Stages and Treatment options for lung cancer
Treatment for NSCLC is stage specific. For patients in early stages (stage I or II), a lobectomy or
a surgical resection is indicated, which can be followed up with adjuvant chemotherapy to clear
remaining cancer cells. Radiation prior to surgical resection may also be administered to shrink
tumors before surgery. Patients with specific mutations, such as overexpression of epidermal
growth factor receptor (EGFR) mutations may qualify for targeted therapy (22).
For patients with Stage IIIA NSCLC, treatment often includes some combination of radiotherapy,
chemotherapy, and surgery; targeted therapy may also be given depending on a patient’s genomic
profile. Primary chemotherapies utilized for the treatment of NSCLC include platinum-based
drugs (i.e. cisplatin), etoposide (topoisomerase II inhibitor), and microtubule poisons (i.e.
docetaxel and paclitaxel) (23,24) For patients with Stage IIIB NSCLC, the tumors cannot generally
be removed by surgery; therefore, chemoradiation may be utilized for treatment, as well as
immunotherapies such as pembrolizumab (3).
For NSCLC patients diagnosed at Stage IV, where the disease has spread, treatment options vary
depending on the extent of metastasis and patient overall health. Clinical recommendations range
to include treatments such as surgery, chemotherapy, radiotherapy, targeted therapy, or
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immunotherapy. Depending on the site of spread and the number of sites detected, stereotactic
radiation may be given. Furthermore, certain gene mutations, such as EGFR, BRAF, or ALK genes,
may allow for the use of specific targeted therapies (3).
The nature of the tumor cell response to radiation and chemotherapy can vary. The general
consensus appears to be that radiation induces delayed cell death, possibly through mitotic
catastrophe, and other direct cell death responses including apoptosis and possibly necrosis.
Several cell survival mechanisms are also activated as alternative cell fates as the cell attempts to
repair damaged DNA and remove injured organelles to evade killing. Tumor cells exposed to
ionizing radiation and chemotherapy invariably also undergo autophagy and senescence as
possible strategies to escape cell death.

1.2. Apoptosis
Cell death is the desired outcome for anti-tumor therapies. In this regard, most standards of care
induce some degree of apoptotic cell death in response to radiotherapy and chemotherapeutic
options. Apoptosis is a process of programmed cell death characterized by chromatin
condensation, DNA fragmentation, cell shrinkage, membrane blebbing, and formation of apoptotic
bodies (25).
There are two major apoptotic pathways: the intrinsic or mitochondrial pathway and the extrinsic
or death receptor pathway (26). The intrinsic pathway is triggered by pore formation in the
mitochondria by the Bax and Bak proteins, resulting in mitochondrial outer membrane
permeabilization (MOMP) and release of cytochrome C from the mitochondrial intermembrane
space (26). Release of cytochrome C promotes apoptosome formation through Apaf-1 and procaspase 9, ultimately contributing to cleavage of pro-caspase 9 to caspase 9. Activated caspase 9,
then cleaves and activates caspase 3, initiating executioner caspases which activate cytoplasmic
3

endonucleases and proteases degrading nuclear components and cytoskeletal proteins (26). The
extrinsic pathway is triggered by binding of a trimeric ligand to a transmembrane receptor, called
the “death receptor”, such as tumor necrosis factor (TNF)-related apoptosis-inducing ligand
(TRAIL) and FAS (27). Binding of ligands to the death receptors activates the formation of a
multi-protein complex, the Death-Inducing Signaling Complex (DISC), and recruitment of adapter
proteins for catalytic cleavage and activation of caspase-8. Activated caspase-8 can cleave and
activates caspase 3 (26). Both the intrinsic and extrinsic pathways converge on caspase 3, leading
to mass degradation of intracellular components.
Under ideal conditions, clinicians aim to selectively optimize apoptotic cell death in tumor cells,
while limiting toxicity and cell death in healthy tissue. However, this is not necessarily the outcome
for all patients. Adverse toxicities to cytotoxic anti-tumor therapies often result in lower tolerated
doses and reduce the extent of apoptosis, while collaterally inducing sufficient damage for tumor
cells to upregulate several cellular survival mechanisms (28,29).

1.3. Autophagy

1.3.1. General Introduction and history
The word autophagy is derived from the Greek words “auto” meaning self and “phagy” meaning
eating to describe the cells’ distinct self-degradative process designed to maintain organellar and
energy turnover during injurious events (30). Accordingly, autophagy is an evolutionarily highly
conserved intracellular catabolic process through which proteins, organelles, and pathogens are
degraded for waste elimination or repurposed for the anabolic cellular needs (31). Autophagy is
frequently activated as part of homeostatic processes in response to cellular stresses, such as
hypoxia or nutrient deprivation (32,33).
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The term “autophagy” was first coined by Christian de Duve in the 1960s while studying
lysosomes, for which he later won the Nobel Prize in Physiology or Medicine in 1974. Using
electron microscopy, he observed what appeared to be a double membrane vesicle sequestering
elements of the cytoplasm and other cellular organelles (34); thus, de Duve was able to describe
the end stages of autophagy and identify autophagy morphologically. It was not until the 1990’s
that the mechanistic components of autophagy were demonstrated by Yoshinori Ohsumi and
colleagues, who identified the numerous genes involved in the autophagic machinery and
phagophore formation by investigating autophagy mutants in yeast for which they also received
the Nobel Prize in Physiology or Medicine. These studies provided the backbone for our current
understanding of the autophagic molecular mechanism. As of this writing, 31 autophagy-related
genes (ATG) have been discovered, coding for various components of the autophagic machinery
and essential components required for macroautophagy. Through loss-of-function studies, it has
been demonstrated that autophagy is important for multiple aspects of an organism’s lifespan,
including maintaining cellular and tissue homeostasis, metabolism, immunity, protection against
aging and early differentiation and development, as well as its role in disease states such as cancer
(35).

1.3.2. Types of Autophagy
Autophagy often incorporates a broader, more ubiquitous degradative process, but in fact there are
multiple types of autophagy. The three primary types of autophagy include: macroautophagy,
microautophagy, and chaperone-mediated autophagy (31). In macroautophagy, components of the
cytoplasm and dysfunctional organelles are sequestered into the growing phagophore, which is a
de novo cytosolic double-membrane vesicle that engulfs cytoplasmic proteins and organelles and
delivers them to the lysosome (30). Microautophagy occurs when cargo is directly taken up
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through the invagination of the lysosomal membrane (36). While macro- and microautophagy can
vary in their selectivity for the recycled cellular components, chaperone-mediated autophagy
(CMA) is highly specific (37). CMA involves the transport of unfolded proteins directly into the
lysosomal membrane by heat-shock proteins, which recognize a specific consensus motif on the
target protein (31,37).
Autophagy can be a selective or nonselective degradative process. Various adaptor proteins are
involved in the sequestration of specific cargo into autophagosomes through the recognition of
cargo tagged with distinct degradative signals, such as neighbor of BRCA1 (NRB1), which works
with p62 to recognize mono-ubiquitylated peroxisomes in pexophagy (38,39), and Nip3-like
protein X (NIX), which is important in the clearance of mitochondria during mitophagy (39,40).
However, for the remainder of this dissertation, we will focus on macroautophagy, which we will
refer to as autophagy.

1.3.3. Autophagic Machinery
During the macroautophagic process, a double-membrane compartment (vacuole) is formed, the
vacuole fuses with the lysosome, and the degraded contents of the vacuole are released into the
cytosol (Figure 1.1). Under normal conditions, mammalian-target of Rapamycin (mTOR)
complex 1 negatively regulates autophagy by phosphorylating and binding to Unc-51 Like
Autophagy Activating Kinase 1 (ULK-1), thus inactivating ULK-1 (41). Under conditions of
cellular stress, ULK-1 becomes dephosphorylated and dissociates from mTOR (41). Initiation of
autophagy occurs through the activation of the ULK-1 complex, which triggers the nucleation of
the phagophore through phosphorylation of PI3KC3, VPS34, and Beclin-1 (BECN1) (42,43).
While the source of the pre-autophagosomal structure is not fully understood, there is literature
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evidence supporting phagophore generation from the endoplasmic reticulum (44), mitochondria
(45), Golgi apparatus (46), and recycling endosomes (47).
Initial biogenesis of the autophagosome begins with the formation of the phagophore that is further
elongated by the recruitment of autophagy regulatory proteins (ATG), such as ATG5 and ATG7.
Microtubule-associated protein light chain 2 (MAP1-LC3) is lipidated by ATG3-mediated
conjugation and incorporated into the growing phagophore, and is necessary for the closure,
fusion, and maturation of the autophagosome (48,49). Cargo is sequestered into the
autophagosome by SQSTM1/p62, a sequestrosome that binds ubiquitinated protein and anchors
itself to LC3 located on the inner membrane of the autophagosome (49). The growing phagophore
extends until the two ends join and fuse together to form a double-membrane vesicle or the
autophagosome. In the final step, the mature autophagosome fuses with the lysosome to form the
autolysosomes. The acidic hydrolases of the lysosome degrade the cargo within the
autophagosome, which is then released into the cytoplasmic space for cellular repurposing (50).
Activation of autophagy is regulated by a plethora of stress factors, including hypoxia, nutrient
starvation, ATP/AMP levels, ROS, and microbial infection (51). Increasing reactive oxygen
species (ROS) generation results in damaging oxidation of lipids, proteins, and DNA, as well as
mitochondrial dysregulation contributing to further accumulation of oxidative stress (51).
Metabolic stress deregulating ATP/AMK ratios and mitochondrial dysfunction activates 5' AMPactivated protein kinase (AMPK), which directly and indirectly modulates autophagy. AMPK
inhibits mTOR, an inhibitor of autophagy, through TCS2 and raptor phosphorylation; thus, AMPK
activation indirectly induces autophagy (52). Furthermore, under stressed conditions, AMPK can
directly phosphorylate ULK1 complexes important for the initiation of autophagy (53) and can
contribute to autophagosomal maturation and lysosomal fusion (54). Oxidative stress also activates

7

and stabilizes hypoxia-inducible factor-1 (HIF-1a), which results in its subsequent nuclear
translocalization and regulates the gene transcription of essential autophagy machinery (55). HIF1a can regulate autophagy indirectly by altering glucose metabolism, mTOR regulation, and
unfolded protein responses (55).
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Figure 1.1 Schematic representation of the macroautophagic process.
A number of cellular stresses, including but not limited to hypoxia, nutrient deprivation and
therapy-induced damage resulting in mitochondrial and genotoxic stress, activate autophagy as a
means to prevent damage accumulation and replenish intracellular nutrients. In this figure, green
arrows demonstrate positive regulators of autophagy, while red indicators demonstrate negative
regulators. AMPK is activated in cells undergoing stress or bioenergetic dysregulation resulting in
mTOR inhibition, which otherwise negatively regulates autophagy by binding and inactivating
ULK-1. Under stressed conditions, ULK-1 is dephosphorylated and dissociates from mTOR, and
triggers nucleation of the phagophore through activation of beclin-1 and PI3K complexes.
Elongation and maturation of the growing phagophore are carried out by essential ATG proteins,
including ATG5 and ATG12, and lipidation of LC3-I to LC3-II and its subsequent incorporation
into the autophagosome membrane. Cargo sequestration is mediated through p62 recognition of
ubiquitinated targets and trafficked into the growing autophagosome where p62 anchors itself to
LC3-II. Lastly, the mature autophagosome fuses with the lysosome, and the catalytic hydrolases
of the lysosome degrade the autolysosomal cargo, which is exported back out into the cytoplasm
for repurposing. Created with BioRender.com.
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1.3.4. Autophagy and Disease
Dysfunctional autophagy has been associated with a number of cardiac and neurodegenerative
disease states, such as Parkinson disease, Alzheimer Disease, and Huntington disease (56).
Alternatively, autophagy has been implicated to have dual functions in cancer development and
therapeutics, exhibiting both tumor-promoting and tumor-suppressing roles. Mice with Beclin-1-/embryonic stem cells were shown to die during embryogenesis, suggesting that autophagy is
essential in early development. More intriguingly, a greater number of haplosufficient Beclin-1+/mice developed spontaneous tumors when compared to wild-type (wt) mice, suggesting that
Beclin-1 may serve as a tumor-suppressor gene, and mutations in Beclin-1, consequently resulting
in autophagy dysregulation, could contribute to tumorigenesis (57–59). With regard to the tumorsuppressive effects of autophagy, induction of autophagy prevents the accumulation of damaged
organelles, protein aggregates and promotes the removal of oncogenic proteins (60–62).
Furthermore, autophagy induction in healthy tissue functions as a tumor-suppressive mechanism
by removing dysfunctional mitochondrial and ROS that may cause DNA damage, thereby
maintaining genomic stability (51,61). Autophagy induction also plays a role in eliciting an
immune response through modulation of immunogenic-cell death (ICD) by contributing to the
secretion of danger-associated molecular patterns (DAMPs), such as ATP (63), secretion of
cytokines, as well as antigen processing (64–71).
In tumor cells, depending on the extent of genomic and cellular damage, autophagy can promote
tumor cell survival through clearance of protein aggregates and damaged organelles incurred by
cytotoxic therapy to allow tolerance of stress (72–74). The catabolic processes of autophagy also
provide metabolic intermediates and raw materials, which feed into the intracellular anabolic
processes, permitting the maintenance of cellular bioenergetics (75,76). Studies by Guo et al.
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demonstrated that RAS-expressing tumors had elevated levels of basal autophagy, and relied on
mitophagy-induced clearance of dysfunctional mitochondria and maintenance of metabolically
functional mitochondria for survival (75); that is these types of tumors could be described as being
autophagy-dependent or autophagy-addicted.
Autophagy can also aid to maintain low intracellular levels of ROS that contribute to activation of
pro-survival pathways, such as Src and NfkB (77,78), resulting in tumor promotion (51,79,80).
Moreover, HIF-1a induced autophagy may contribute to tumor resistance to anti-cancer
treatments, and inhibition of autophagy may restore sensitivity to therapy (81,82). While
autophagy is implicated in tumorigenesis, functioning as both a tumor-promoting and tumorsuppressing mechanism, autophagy is also induced in response to therapy as a potential mechanism
to prevent damage accumulation (83,84).

1.3.5. Autophagy in response to cancer therapy
Cytotoxic therapies, acting through a multitude of mechanisms, rely largely on extended damage
and impaired cellular functions to activate cell death machinery. In an effort to mitigate the
cytotoxic effects of cancer therapies, autophagy is often, if not uniformly, activated to remove
protein aggregates, nuclear damage, and/or depolarized mitochondria (85). Removal of these
damaged moieties serves to evade activation of apoptotic cell death pathways and provides the raw
material necessary for metabolic processes (86); however, depending on the extent of damage,
excessive autophagy activation can also potentially result in cell death (87).
Extensive pre-clinical and clinical studies have demonstrated autophagy induction in response to
therapy (83,88,89). Although the desired outcome of radiation and chemotherapy is tumor cell
death by a pathway such as apoptosis, it is not obligatorily the sole or primary response to radiation
and chemotherapy. While the effectiveness of clinical therapy in promoting tumor shrinkage may,
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of necessity, ultimately involve apoptosis, studies in tumor cells in culture clearly indicate that a
consistent and uniform initial response to radiation and chemotherapy is autophagy (90–93).
Studies by Ren et al. utilizing 30 NSCLC patient tissue samples subjected to 2 Gray (Gy; a
clinically relevant dose of radiation), assessed LC3 and SQSTM1/p62, markers of autophagy, by
immunohistochemical staining. Of these 30 samples, 26 demonstrated significant upregulation of
LC3 and downregulation of SQSTM1/p62, indictive of autophagy induction (88,89,91,94,95).
Screening was performed in which U20S osteosarcoma cells were exposed to 80 National Cancer
Institute (NCI) anticancer drugs and the extent of apoptosis, autophagy, and necrosis were
measured. Of these 80 cytotoxic drugs, 59 drugs induced autophagosome formation and
demonstrated autophagic flux in studies where the cells were also exposed to bafilomycin A1
(BafA1), a pharmacological inhibitor of autophagic flux (96). The remaining 21 drugs produced
predominantly necrosis and apoptosis, with little autophagic flux. These latter agents were further
characterized as microtubule inhibitors, which may in part be due to the necessity of microtubules
for autophagosome localization and migration to lysosomes (97). There is an indisputable
complexity to the cellular responses activated by chemotherapy, and of those responses, autophagy
is clearly induced in tumor cells by many anticancer therapeutics (Figure 1.2).
1.3.5.1.Autophagy in response to DNA damaging therapy.
A primary mechanism whereby a number of anticancer drugs, such as platinum-based compounds
and topoisomerase I/II poisons, exert their cytotoxic effects is through DNA damage. DNA double
strand breaks (DSB) activate Ataxia-Telangiectasia mutant (ATM), which in turn can activate
Chk1/2 as well as AMPK (98). ATM, itself, and activated Chk1/2 can phosphorylate and stabilize
p53 (99–101), which, in turn modulates the transcription of key autophagy-related genes as well
as damage-regulated autophagy modulator (DRAM), resulting in autophagy induction (98,102).
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Autophagy also plays a role in DNA damage repair by providing metabolic precursors for ATP
generation required by several DNA damage response (DDR) pathways, maintains dNTPs needed
for DNA replication and repair, and plays a role in the turnover of key proteins involved in DDR
and DSB processing (103). Lin et al. demonstrated that cisplatin, an alkylating agent that generates
bulky adducts on DNA, induced autophagy through Beclin-1 activation in human bladder cancer
(104). Similarly, Li et al. demonstrated that interference with autophagy by 3-MA or siRNA
targeting ATG7, both in vitro and in vivo, sensitized colorectal cells to 5-fluorouracil (5-FU), a
pyrimidine analog and antimetabolite (105). Aydinlik et al. showed autophagy induction in
response to doxorubicin, a topoisomerase II inhibitor, in triple-negative breast cancer cells;
furthermore, autophagy inhibition increased doxorubicin-induced cell death and increased
sensitivity (106).
Therapies such as radiotherapy induce excessive damage throughout the cell through direct DNA
damaging capabilities and through the indirect generation of ROS (81,82,107,108). Both DNA
damage and ROS are well characterized as inducers of autophagy. Ito et al. showed that radiation
exposure in malignant glioma cell lines induced autophagy and cell cycle arrest, instead of
apoptosis (95).
1.3.5.2.Autophagy in response to non-DNA damaging therapy

Autophagy is also induced in response to multiple chemotherapeutic modalities which are not
considered to directly promote DNA damage. Moreover, as therapeutic approaches, such as
targeted therapies and immunotherapy, have become an additional element of anticancer treatment
regimens, autophagy has also been shown to be induced in response to a variety of such novel
agents. For example, tamoxifen and other anti-estrogens induce protective autophagy in breast
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cancer (109). Histone deacetylase (HDAC) inhibitors, such as butyrate and SAHA, were shown to
induce autophagy, and more specifically autophagic cell death in cervical cancer (110). The
epidermal growth factor receptor (EGFR) represents a major target for a variety of monoclonal
antibodies for the treatment of different cancer types. EGFR activates several downstream prosurvival pathways, including Ras/MAPK, Jak/Stat, and PI3K/AKT/mTOR signaling pathways
(111). While EGFR inhibitors are often effective, many cancer patients become resistant to these
therapies; thus, further understanding of and manipulation of autophagy may serve as a potential
therapeutic strategy for sensitization of patients to anti-EGFR therapies. In support of this
approach, Li et al. demonstrated autophagy induction in response to cetuximab, an EGFR-blocking
antibody, via inhibition of mTOR and activation of Beclin-1 in human vulvar squamous
carcinoma, colorectal cancer, and NSCLC (112). Autophagy induction was further demonstrated
in response to targeted therapy in studies where hepatocellular carcinoma (HCC) cells were shown
to undergo autophagy in response to linifanib, a vascular endothelial growth factor (VEGF) and
platelet-derived growth factor (PDGF) inhibitor, through suppression of PDGFR-b and its
downstream signaling pathways, in vitro and in vivo (113).
1.3.5.3. Non-cell autonomous effects of autophagy.
Autophagy modulation may mediate both cell-autonomous (direct cellular) and cell nonautonomous effects, the latter related to surrounding cells, such as immune, epithelial, and other
tumor cells in the TME. Immune evasion by tumor cells remains a major barrier to effective cancer
treatment. Tumor cells can develop multiple mechanisms to evade host-mediated immunity, such
as impaired/downregulation of antigen presentation and upregulation of immune checkpoints,
which downregulate T-cell activity (114). Yamamoto et al. demonstrated that major
histocompatibility complex class I (MHC-I), a molecule important in antigen presentation, was
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adenocarcinoma (PDAC) cell lines (115). Furthermore, in a mouse model of PDAC tumor cells
expressing a doxycycline-inducible dominant-negative ATG4B knockdown, autophagy inhibition
was shown to increase MHC-1 expression and CD8+ T cell activation, enhanced T-cell mediated
killing and consequently a reduced tumor cell viability (115). Reduced tumor burden and increase
tumor-infiltrating T cells were also evident in a similar model with knockdown of ATG7 (115).
Given that PDAC is refractory to immune-checkpoint blockade (ICB), the authors examined
whether autophagy inhibition would sensitize tumors to immune-checkpoint inhibitors. Utilizing
a syngeneic mouse model with orthotopic tumors, Yamamoto et al. demonstrated a significant
reduction in tumor volume and increased CD8+ T cell infiltration in the ATG4B knockdown mice
compared to autophagy-proficient mice when exposed to dual ICB (anti-PD-1 and anti-CTLA4).
Furthermore, administration of CQ significantly sensitized tumors to the ICB therapy. Finally,
Liang et al. also demonstrated autophagy induction in response to high-dose interleukin-2 (IL-2)
treatment in a model of advanced metastatic murine liver tumors (116). Addition of CQ with IL-2
therapy increased immune infiltration, reduced tumor burden, and increased survival. These data
suggest that autophagy inhibition may be a potential strategy for the sensitization of patients to
immune-checkpoint therapy.

15

Figure 1.2. Autophagy induction in response to therapy.
Anticancer therapies work through multiple mechanisms of action, such as genotoxic stress,
oxidative stress and increase ER and mitochondrial damage. Genotoxic therapies, such as cisplatin
and etoposide, incur DNA damage, activating DNA damage response and p53 pathways. p53
activation can promote the transcription of autophagy-related genes (ATG’s), which contribute to
components of the autophagic machinery. Stress, chemotherapy and radiation can also induce
protein and organelle damage, as well as the accumulation of misfolded proteins. Excessive
aggregation of unfolded proteins activates the unfolded protein response, UPR, in the ER, which
promotes autophagy as a means to alleviate the burden unfolded/misfolded proteins and maintain
homeostasis. Aside from increased ER stress, multiple chemotherapies and radiation promote the
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generation of ROS levels as well. Increased cellular ROS levels and oxidative stress triggers HIF1𝑎 activation. HIF-1𝑎 can translocate into the nucleus and promote transcription of ATG genes;
thus, inducing autophagy to prevent the accumulation of oxidative stress. Furthermore, increasing
levels of ROS oxidize surrounding proteins resulting in oxidative damage and malfunction, as well
as dysregulation of mitochondrial bioenergetics, exacerbating damage and activate intrinsic
apoptotic pathways. The resulting metabolic dysfunction increases intracellular ATP, which can
be shuttled into the extracellular space, bind to purogenic receptors on T cells, and promote
recruitment. Autophagy has been shown to play a role in ecto-ATP release in dying cells and
promote immune recruitment and clearance of tumor cells. Lastly, therapies, such as EGFR
inhibitors, block tyrosine kinase receptor signaling cascades promoting mTOR activation, a known
inhibitor of autophagy; therefore, EGFRi block upstream receptor signaling, resulting in mTOR
inhibition and Beclin-1 activation. Taken together, autophagy is involved and induced in response
to multiple cytotoxic therapies through a multitude of intracellular pathways as a means to prevent
the accumulation of damage incurred by therapy. Created with BioRender.com.
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1.3.6. Functional forms of autophagy
While autophagy is routinely observed in tumor cells in response to chemotherapy and radiation,
the functional contribution of autophagy to the overall outcome of therapy can vary depending on
a number of factors, including but not limited to, the type of therapeutic utilized, time of treatment,
dose, type of cancer and cell type. Autophagy can play multiple functions in response to
chemotherapy and radiation treatment; however, the functional form of autophagy can only be
determined through the impact on drug or radiation sensitivity when the autophagy is inhibited
either pharmacologically and/or genetically. Conventional pharmacological inhibition, using
agents such as chloroquine (CQ), Bafilomycin A1 (BafA1) or 3-methyladenine (3-MA), or genetic
silencing techniques, including siRNA or shRNA knockdown or cell-specific gene knockout of
Beclin-1 and essential ATG proteins, can be utilized to determine the functional form of autophagy
induced by a particular treatment (Table 1).
1.3.6.1.Cytoprotective Autophagy.
One of the best-known functions of autophagy is its conventionally cytoprotective function in
response to cellular stresses, such as serum starvation or hypoxia. In this scenario, pharmacological
and genetic inhibition of autophagy increases sensitivity to the anticancer treatment that promotes
autophagy (117,118). Increased sensitivity is often associated with the activation of cell death
pathways, apparently indicating that autophagy was acting as a protective cellular mechanism for
the evasion of cell death (119,120). In most of the current literature, autophagy is considered to
have a cytoprotective function; consequently, inhibition of cytoprotective autophagy would be
anticipated to result in radiosensitization and chemosensitization. Early work performed by
Chaachouay et al. showed that autophagy inhibition with 3-methyladenine (3-MA) and
chloroquine (CQ) radiosensitized MDA-MB-231 (MDA-231) and HBL-100 breast cancer cells
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(92). Similarly, CQ was also shown to sensitize bladder cancer cells to radiotherapy both in vitro
and in vivo and to promote apoptosis when autophagy inhibition was combined with radiation
(121). Additionally, Qadir et al. demonstrated that autophagy inhibition sensitized MCF-7 breast
tumor cells to tamoxifen. In these studies, sensitization was due to increased mitochondrial
dysregulation and caspase 9-mediated apoptosis, indicating that inhibition of cytoprotective
autophagy increased cell death (122). Similarly, Selvakumaran et al. showed that autophagy was
induced in response to oxaliplatin in multiple colon cancer cell lines, and administration of CQ
significantly reduced tumor volume in response to oxaliplatin and bevacizumab in HT29-derived
orthotopic mouse tumors (123).
A number of miRNAs have also been identified that mediate autophagy (124). The expression of
miRNA-30a (miR-30a) is downregulated in several renal carcinoma cell (RCC) lines and patient
samples and has been shown to inhibit autophagy through Beclin-1 downregulation. Knockdown
of miR-30a significantly increased Beclin-1 expression and interfered with the cytotoxic effects of
sorafenib, a multikinase inhibitor, in RCC cells (125). Pharmacological autophagy inhibition
through CQ, 3-MA, and BafA1 reduced cell viability and increased cell death in RCC cells treated
with sorafenib, indicating that autophagy was playing a cytoprotective function in response to
sorafenib (125). Collectively, these studies demonstrate the functional capacity of autophagy to
protect tumor cells challenged by anticancer therapy.

Resistance Induction of cytoprotective autophagy has also been implicated in resistance to therapy
and can facilitate multidrug resistance (126). Utilizing epirubicin-resistant MCF-7er and SK-BR3er cells, Sun et al. examined the role of autophagy in multi-drug resistance (127). MCF-7er and
SK-BR-3er cells were collaterally insensitive to paclitaxel and vinorelbine compared to parental
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cells. Genetic silencing of Beclin-1 and ATG7 in MCF-7er and SK-BR-3er restored sensitivity to
paclitaxel and vinorelbine. Anthracycline-resistant MDA-MB-231-R8 and SUM159PT-R75 cells
exhibited higher basal autophagic flux than parental cells (128). Genetic knockdown of ATG5/7
and pharmacological inhibition of autophagy with CQ or hydroxychloroquine (HCQ) significantly
sensitized both epirubicin-sensitive and resistant triple-negative breast cancer cell lines. These
studies support the concept of autophagy functioning as a cytoprotective mechanism employed by
the tumor cells to avert cell death, and that manipulation of these processes could hold therapeutic
potential.
Autophagy induction can also play a role in resistance by contributing to cancer stem cell
maintenance. Cancer stem cells are a subpopulation of tumor cells that have self-renewal and
differentiation capabilities and can contribute to resistance to anti-cancer therapy and disease
reoccurrence (129,130). Lomonaco et al. investigated the role of autophagy in radioresistant
glioma stem cells (GSC). CD133+ GSC cells exhibited a greater extent of autophagy when
exposed to g-radiation compared to CD133- cells; moreover, exposure to BafA1 or genetic
knockdown of Beclin-1 and ATG5 significantly reduced cell viability (93). These data suggest that
autophagy is protective in response to g-radiation in CD133+ GSC cells.
Additionally, acidic lysosomes can trap weakly basic drugs, such as doxorubicin and irinotecan,
thereby reducing drug efficacy and conferring resistance. Guo et al. examined the role of
autophagy in doxorubicin localization as MCF-7 cells acquired resistance to increasing doses of
doxorubicin (131). Their studies demonstrated increased autophagy induction and sequestration of
doxorubicin within lysosomes as MCF-7 cells developed resistance to doxorubicin treatment;
furthermore, autophagy inhibition with CQ was sufficient to restore sensitivity in doxorubicinresistant MCF-7 cells.
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While autophagy inhibition may have beneficial outcomes, in a cell-autonomous manner, the
effects of autophagy inhibition on surrounding cells, or the cell non-autonomous aspects, must also
be considered. Thorburn et al. demonstrated that silencing of ATG5 and ATG7 in MDA-MB-231
TRAIL-sensitive breast tumor cells resulted in increased outgrowth of GFP-tagged TRAILresistant cells when compared to autophagy-proficient controls (132). Furthermore, autophagy
inhibition through an inducible shATG12 model in a population of GL261 glioma cells sensitive
to EGF inhibition promoted outgrowth of GFP-tagged EGF-resistant cells. Through these studies,
Thorburn et al. also demonstrated that autophagy inhibition in drug-sensitive cells induced caspase
activation, and the subsequent stimulation of prostaglandin E2 (PGE2) signaling promoted tumor
repopulation of drug-resistant cells (132,133). Taken together, autophagy inhibition may increase
cell killing and sensitize drug-sensitive cells to therapy; however, this may promote the selection
and growth of a resistant population, which may have detrimental therapeutic outcomes. Thus,
there is an intricacy to autophagic function in response to chemotherapy and radiation that must
be considered prior to the adoption of autophagy inhibition therapy.
1.3.6.2.Cytotoxic Autophagy.
The generally accepted premise that autophagy is cytoprotective in cells in response to stress has
spilled over to establishing its cytoprotective function in response to anticancer therapy in tumor
cells. Extensive preclinical data in a number of experimental tumor models and in response to
various chemotherapeutic agents does support the cytoprotective function of autophagy based on
the observations outlined in the previous section. However, it should be emphasized that preclinical data has, in fact, demonstrated that autophagy can be divergent from this protective
function and exhibit both a cytotoxic activity as well as, in certain cases, failing to modulate the
tumor response to therapeutics.
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Autophagy modulation may appear as a desirable therapeutic target; however, it is important to
acknowledge the multi-functional nature of autophagy. In response to chemotherapy and radiation,
cells can also undergo a cytotoxic form of autophagy, resulting in reduced cell viability and
clonogenic survival. Cytotoxic autophagy can kill tumor cells through both apoptosis-dependent
and independent mechanisms (117,134,135). When autophagy takes on a cytotoxic function,
autophagy inhibition reduces tumor cell sensitivity to therapy and promotes cell viability. Studies
by Talarico et al. examined the effects of SI113, a selective SGK1 serine/threonine inhibitor, in
combination with radiotherapy on human glioblastoma multiforme (GM) cells (136).
Administration of SI113 significantly reduced cell viability and oxidative stress in GM cell lines
exposed to 5, 8, or 10 Gy of radiation. The authors demonstrated that SI113 induced autophagy
and that the addition of CQ abolished the cytotoxicity of SI113, thus indicating that the antitumor
effects of SI113 were mediated through induction of cytotoxic autophagy. Kanzawa et al.
demonstrated autophagy inhibition with 3-MA and genetic silencing ameliorated temozolomide
anti-tumor effects (137). Indeed, autophagy inhibition when the autophagy is protective in nature
is a potential therapeutic to be exploited as a means of sensitization; however, when the autophagy
is toxic in function, this can result in detrimental outcomes, such as tumor survival and drug
resistance.
1.3.6.3.Cytostatic Autophagy.
Autophagy can also exhibit a cytostatic function in response to cancer therapeutics. Of the
functional forms of autophagy, this is perhaps the least understood, although it is logical that cells
exposed to stress might arrest and fail to continue to progress normally through the cell cycle.
In the case of cytostatic autophagy, therapy-induced growth inhibition and sensitivity is mediated
through autophagy, rather than apoptosis; furthermore, autophagy interference restores cellular
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proliferation and ameliorates antitumor therapeutic effects (117,138). For instance, work by
Sharma et al. demonstrated cytostatic autophagy in response to EB 1089, a vitamin D analog, in
NSCLC cells when combined with radiation (139). The authors show that administration of EB
1089 or 1,25-D3 significantly sensitized H460 NSCLC cells to radiation. Sensitization was not
associated with increased DNA damage, apoptosis, or necrosis, or senescence, but rather these
cells exhibited a more pronounced growth arrest, which was characterized as a form of cytostatic
autophagy. Autophagy inhibition through CQ administration, shATG5 or ShBECN1 knockdown
sensitized H460 cells to radiation alone, indicative of radiation-induced cytoprotective autophagy
in H460 cells; however, in cells treated with EB 1089 and radiation, autophagy inhibition reversed
the sensitization induced by EB 1089.
Studies by Dou et al. also demonstrated cytostatic autophagy in breast cancer cells exposed to
ivermectin, an antiparasitic drug with anticancer therapeutic potential (140). The authors showed
that ivermectin was sufficient to suppress breast cancer cell proliferation and tumor burden, in
vivo. Breast cancer cells were shown to undergo little or no significant apoptosis in response to
ivermectin but did undergo autophagy. Furthermore, autophagy inhibition was sufficient to
attenuate the antiproliferative effects of ivermectin in breast cancer cells with no significant impact
on the extent of apoptosis, suggesting that ivermectin’s antiproliferative effects are mediated
through induction of cytostatic autophagy (140). Whether cytostatic autophagy sensitizes tumor
cells to therapy by contributing to the induction of quiescence or senescence is not well understood,
and in fact, there is no literature evidence delineating the differential activation of either
senescence or quiescence in the case of cytostatic autophagy.
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1.3.6.4.Nonprotective Autophagy.
A novel function of autophagy in response to therapy is the nonprotective form. In previous studies
from our own laboratory, we identified the “non-protective” form of autophagy (141). This is a
functional definition wherein autophagy is induced in response to radiation or chemotherapy but
where subsequent inhibition of autophagy fails to alter radiation sensitivity (142). Eng et al.
demonstrated that both pharmacological inhibition of autophagy with CQ and Lys01, and genetic
inhibition by genome editing of ATG7 did not alter sensitivity to radiation (or 30 different
chemotherapies) of KRAS mutant tumors in vitro and in vivo. Further, they were able to show that
CQ-mediated sensitization was independent of autophagy, suggesting the antiproliferative effects
may be due to modulation of off-target effects (143,144). Similarly, studies performed by Schaaf
et al. demonstrated that radiosensitization effects of CQ, 3-MA, and ATG7 deficiency were
independent of canonical autophagy pathways and may involve effects on lysosomal degradation
(145).
In a seminal paper by Michaud et al, autophagy that was induced in colorectal cancer cells by
oxaliplatin or mitoxantrone proved to be nonprotective in function, in that silencing of the
autophagy gene, ATG7, failed to influence drug sensitivity in the tumor cells in vitro (146).
Intriguingly, work by Cechakova et al. suggested that Lys05, an autophagy inhibitor, could
radiosensitize H1299 (p53 null) cells, indicating a cytoprotective autophagic function in these
NSCLC cells (147). However, a closer examination of data revealed the observed sensitization is
modest in effect, and unlikely to be therapeutically relevant, indicating that the autophagy is likely
acting in a nonprotective fashion. This observation serves to confirm the findings from our own
laboratory where we reported radiation-induced nonprotective autophagy in the same H1299 (p53
null) cells, i.e. wherein autophagy inhibition likewise failed to alter radiosensitivity (141).
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As exemplified through the literature presented in this section, autophagy exhibits a
multifunctional nature in response to chemotherapy and radiation. Clinical autophagy inhibition
in scenarios where the autophagy is cytoprotective in function proves an advantageous avenue for
chemo-and radio- sensitization. However, the capacity to determine autophagic function in
response to antineoplastic therapy in patients is not considered or screened for prior to the addition
of autophagy inhibitors to therapeutic regimens. This is in part due to the lack of clinical
biomarkers or determinants of autophagic function; thus, in-depth pre-clinical studies are required
to elucidate molecular regulators and conditions modulating the particular functions of autophagy
before routine incorporation of autophagy inhibitors into the clinic.
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Table 1.1. Pharmacological Autophagy Inhibitors.

Autophagy
Inhibitor

Mechanism of
Inhibition

Target

Effective
Inhibitory
Concentration

Reference

CQ/HCQ

Accumulates within
lysosome and prevents
lysosomal fusion

Lysosomal
fusion

5-50 µM

(148,149)

BafA1

V-ATPase inhibitor,
interferes with
lysosomal acidification

Lysosomal
fusion

1-10 nM

(73,150)

Lys05

Dimeric form of CQ,
accumulates in
lysosome

Lysosomal
fusion

10-100 µM

(151,152)

3-MA

Class III PI3K inhibitor, Autophagosome
prevents initiation
formation

1-10 mM

(153,154)

SAR405

Vacuolar protein sorting Autophagosome
protein 18 & 34 (Vps18
formation
and Vps34) inhibitor

1-10 µM

(155–157)

1-20 µM

(158,159)

Spautin-1

Ubiquitin-specific
peptidase inhibitor,
Vps34 inhibitor,
prevents initiation

Autophagosome
formation

LY294002

PI3K inhibitor, prevents Autophagosome
initiation
formation

10-100 µM

(160,161)

Wortmannin

PI3K inhibitor, prevents Autophagosome
initiation
formation

1-10 µM

(162)

SBI-0206965

ULK1 inhibitor,
prevents initiation

Autophagosome
formation

10-50 µM

(163,164)

NSC185058

ATG4B inhibitor

Autophagosome
formation

1-100 µM

(165)

Mdivi-1

Mitochondrial division
inhibitor, inhibits
fission by selective
dynamin-related protein
1 (Drp1) inactivation

Mitophagy

1-10 µM

(166,167)
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1.3.7. p53 and autophagy
A number of molecular pathways have been implicated in regulating autophagy; however, a
protein that seems to be upstream of most of these regulators is p53 (19,168). p53 is a well-known
key tumor suppressor, which is often aberrant in many tumor cell types and is frequently implicated
in early tumorigenesis. Amongst its various cellular functions, p53 plays primary functionals role
in regulating apoptotic cell death, cellular growth arrest, and DNA repair. While p53 has been
shown to regulate autophagy, the nature of the relationship between p53 and autophagy is not
completely established. Depending on spatiotemporal localization, nuclear p53 has been shown to
activate autophagy through transcription of upstream inhibitors of mTOR and through more direct
means, such as DRAM upregulation, which encodes a lysosomal protein inducing macroautophagy
(102). However, on the flip side, cytoplasmic p53 protein inhibits autophagic cell death by
inducing BECN degradation via the ubiquitin-specific peptidases USP10 and USP13 and/or
inhibiting the AMPK-mTOR-ULK1 signaling pathway (169–171). To add further complexity to
this relationship, autophagy can also mediate p53 turnover and degradation (159). Whether p53
activates or suppresses autophagy is not clear; however, this may provide initial insights as to a
potential mediator of the various functional forms of autophagy.
Mutant p53 has also been shown to regulate autophagy to confer chemoresistance in lung cancer
(172). Mutant p53 has been shown to upregulate Nrf2 activity, a transcription factor that codes for
multidrug resistance, antioxidant proteins, and other proteins triggered to protect against oxidative
and chemotoxic damage (173). In this study, Tung et al demonstrated that wild-type p53
suppressed Nrf2 promoter activity in NSCLC cells; however, in p53 mutant cells, promoter activity
was not suppressed, resulting in increased mRNA levels of Nrf2 and upregulated transcription of
the anti-apoptotic proteins, Bcl-2 and Bcl-XL, ultimately, contributing to cisplatin resistance (173).

27

Studies by Saini et al. examined the effects of p53 GOF (gain of function) mutants on cancer cell
resistance to chemotherapy and proteasomal inhibition utilizing H1299 p53 null NSCLC cells
transfected with either wild-type p53, R273H mutant GOF, or empty vector (174). They
demonstrated that R273H-p53 mutant cells were significantly less sensitive to cisplatin and 5-FU
and exhibited multi-drug resistance. While dual treatment with a proteasomal inhibitor, peptide
aldehyde N-acetyl-leu-leu-norleucinal (ALLN), and an autophagy inhibitor did not sufficiently
promote cell death in R273H-p53 mutant cells, activation of autophagy by serum starvation or
rapamycin exposure promoted cytotoxic autophagy and enhanced cell killing through increased
autophagosome accumulation and ROS levels. In contrast, Wu et al. demonstrated that cisplatinrefractory A549 lung adenocarcinoma cells expressing wild type p53 exhibited greater basal
autophagy compared to parental A549 cells; furthermore, treatment with cisplatin increased
autophagy induction (175). Autophagy inhibition with CQ in cisplatin-resistant A549 cells induced
apoptosis and resensitized these cells to cisplatin, suggesting autophagy was cytoprotective in
function in A549 p53 wt cisplatin-refractory cells. Taken together, both NSCLC cell lines
expressing either p53 mutant or wt p53 exhibited differential responses to cisplatin exposure,
indicating that p53 status may impact autophagic function in response to anti-cancer therapy and
that therapy-induced autophagy (TIA) may play a role in the development and maintenance of
chemoresistance.

1.3.8. Autophagy and the Immune Response
Therapy-induced autophagy is an integral component of immunogenic cell death and immune
modulation in response to anticancer therapy. Autophagy plays a role in the release of ATP in
dying cells that act as chemotactic ligands for purogenic receptors on immune cells (176). This
interaction is important in the recruitment of dendritic cells (DC) to the tumor microenvironment
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(TME) and the subsequent activation of T cells to elicit anti-tumor responses (146,177). Studies
by Michaud et al. demonstrated that autophagy induction in vitro did not significantly alter tumor
cell responses to mitoxantrone (MTX) and oxaliplatin (OXA) (68). In dramatic contrast, in
immune-competent mice, autophagy-proficient cells exhibited increased DC and T cell infiltration
compared to autophagy-deficient cells. Autophagy inhibition suppressed ATP release and
subsequent immune recruitment, while increasing exogenous ATP in autophagy-deficient tumors
was able to restore immune infiltration and tumor-suppressive responses (68). These data implicate
a role for autophagy in the release of ATP, a DAMP, and its function in eliciting anti-tumor
immune responses to mitoxantrone or oxaliplatin in mouse colon carcinoma xenografts. Similarly,
Ko et al. examined the immunomodulatory effects of autophagy in response to radiotherapy (176).
These authors demonstrated that shRNA knockdown of ATG5 and Beclin-1 significantly
radiosensitized A549 and H460 NSCLC cells and CT26 colon carcinoma cells, in vitro, and in
immune-deficient mice. However, autophagy depletion reduced radiosensitivity and decreased
ATP release in immune-competent mice, suggesting that autophagy-induced ATP release could
be critical for anti-cancer immune responses (176). Consistent with the studies from Michaud et
al., increasing exogenous ATP in autophagy-deficient tumors was able to restore immune
infiltration and radiosensitize tumors, in vivo (176).
Autophagy modulates immune function through multiple pathways, such as pathogen degradation,
antigen presentation, and processing of cytokines (65,178). Autophagy can also regulate the
trafficking of receptors to the cell surface, which are required for antigen presentation and
complement activation (67,179). Work by Ramakrishnan demonstrated the role of autophagy and
tumor cell lysis by cytotoxic T lymphocytes (CTL). They showed upregulation of the mannose-6phosphate receptor (MPR) in tumor cells exposed to multiple therapies, including cisplatin,
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paclitaxel and doxorubicin, as well as multiple myeloma patient tumor samples (179).
Furthermore, MPR was implicated in chemotherapy-induced anti-CTL responses, reduced tumor
volume, as well as cell killing of bystander tumor cells that did not express tumor antigen.
Autophagy inhibition abrogated paclitaxel-induced MPR cell surface expression in melanoma
cells and doxorubicin-induced MPR expression in multiple myeloma cells, as well as reducing
CTL cytotoxicity (179), implicating autophagy in the regulation of MPR expression on tumor cell
surfaces and CTL cell killing. Taken together, these data indicate the immunomodulatory functions
of autophagy in both innate and adaptive immune responses to chemotherapy and radiation.

1.3.9. Current modalities to modulate autophagy and clinical trials
Current paradigms for clinical administration of autophagy inhibitors to sensitize patients to
chemotherapy and radiation are based on the premise that the autophagy induced is cytoprotective
in function; however, the clinical utilization of autophagy inhibitors has largely produced
inconsistent results (180). Currently, the only clinically approved autophagy inhibitor is
hydroxychloroquine (HCQ), a Food and Drug Administration (FDA)-approved anti-malarial drug
used for prophylactic treatment of malaria, treatment for lupus or rheumatoid arthritis (181). HCQ
acts by inhibiting lysosomal acidification, as well as preventing the fusion of the autophagosome
to the lysosome in the final steps of autophagy (149); however, there are also off-target effects of
HCQ, which still remain elusive (182).
Significant pre-clinical data indicating the cytoprotective function of autophagy in response to
chemotherapy and radiation (92,183,184) provided the foundation for the initiation of a number of
clinical trials to inhibit autophagy as a strategy for sensitization of patients to therapy (Table 1.2).
Studies published by Vogl et al. in 2014 examined the effects of HCQ on the efficacy of
bortezomib, a proteasomal inhibitor, in patients with relapsed/refractory myeloma. The
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combination of HCQ with bortezomib demonstrated partial or minor responses in 6 (28%) of
patients and stable disease in 10 (45%) of patients (148). Furthermore, electron micrographs of
bone marrow plasma collected from patients exhibited greater autophagic vesicles and increased
misfolded protein trafficking with the combination therapy. Patients were given 600mg of HCQ
twice daily with a standard dose of bortezomib and only Grade 2 gastrointestinal toxicity and
cytopenia were observed. Similarly, studies by Barnard et al. examined the effects of HCQ
administration in combination with doxorubicin in canine Non-Hodgkin lymphoma in a Phase I
clinical trial. Canine patients received HCQ orally 72 h prior to standard dose of doxorubicin
treatment. Oral HCQ administration was well tolerated with no significant grade 3 or 4 toxicities.
Combination therapy exhibited a 93% overall response rate in canines with lymphoma, with a
median progression-free interval of 5 months (185). In two separate studies by Levy et al., they
were able to show improved therapeutic efficacy with autophagy inhibitors in combination with
vemurafenib, a BRAFV600E inhibitor (186,187). Mulcahy Levy et al. examined the effects of HCQ
administration in BRAFV600E-mutant brain tumors resistant to vemurafenib. Patients received 500
mg CQ orally daily with continued standard dose of vemurafenib treatment. Improved therapeutic
efficacy was exhibited in resistant patients who received CQ in combination with vemurafenib
(186). Furthermore, increased LC3 II accumulation was seen in peripheral white blood cells in
patients given CQ, suggesting autophagy was sufficiently inhibited. In contrast, a Phase I/II
clinical trial combining HCQ, temozolomide (an alkylating agent), and radiation were performed
in patients with glioblastoma multiforme (89). Doses of 600mg HCQ combined with low dose
temozolomide failed to demonstrate improved overall survival in glioblastoma patients.
Furthermore, when increasing doses to 800mg of HCQ daily combined with temozolomide,
significant Grade 3 and 4 neutropenia and thrombocytopenia were exhibited. Electron microscopic
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images indicated increased autophagic vesicles in patients treated with radiation; however, even
at the higher doses of HCQ, substantial autophagy inhibition could not be demonstrated.
In addition to the dose-limiting side effects of HCQ, another limitation likely contributing to the
inconsistent clinical results is the failure of currently available pharmacological autophagy
inhibitors to sufficiently interfere with autophagy in patients. In order to effectively block
autophagy in patients, significantly higher doses of HCQ would be required, which may result in
undesirable side effects (180). Several other clinical trials have been initiated in order to study the
effects of autophagy inhibition on chemo- and radiosensitivity; however, these provided
inconsistent results. HCQ as a monotherapy in patients with metastatic pancreatic adenocarcinoma
provided inconsistent autophagy inhibition and poor therapeutic efficacy in a phase II trial (188).
Combination of HCQ with docetaxel in patients with metastatic prostate cancer was terminated
early due to a lack of improved efficacy (Identifier: NCT00786682). However, several clinical
trials have been launched utilizing higher doses of HCQ in combination with chemotherapeutics,
such as bortexomib, which may show more promising results (148) (Identifier: NCT00568880,
NCT01206530, NCT01506973).

Table 1.2. Clinical Trials manipulating autophagy inhibition to sensitize cancer patients
to antitumor therapy.
Cancer Type

Treatment

Results

Noted Toxicities

Reference

Relapsed/
refractory
myeloma

600mg of HCQ
twice daily with
a standard dose
of bortezomib

Partial or minor
responses in 6 (28%) of
pts and stable disease
in 10 (45%) of patients

Twice daily with a
standard dose of
bortezomib and only
Grade

(148)

Glioblastoma
Multiforme

600mg or 800
mg HCQ
combined with
low dose

No significant
improvement in overall
survival

At 800mg of HCQ
daily combined with
temozolomide
significant Grade 3

(89)
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temozolomide
and radiation
therapy
Metastatic
prostate
cancer

and 4 neutropenia
and
thrombocytopenia

HCQ with
docetaxel

Early termination due
to a lack of improved
efficacy

Identifier:
NCT007866
82

High Grade
Glioma

lower doses of
HCQ and short
course
radiotherapy

When compared to
radiation alone,
combination did not
improve patient
outcome

Grade 3-5 toxicities

(189)

Metastatic
Pancreatic
adenocarcino
ma (did not
respond
to
conventional
therapy)

400 or 600 mg
HCQ, twice
daily as a
monotherapy

10% (2 out of 20 pts)
achieved 2-month PFS
(poor therapeutic
efficacy) and
inconsistent autophagy
inhibition

2 patients
experienced Grade
3/4 lymphopenia and
elevated alanine
aminotransferase

(190)

Advanced
Solid tumors
and
melanoma

Combined
temsirolimus
(rapamycin
analog) (25 mg,
weekly) with
600 mg, twice
daily of HCQ

67% of pts reached
stable disease. Tumor
biopsies demonstrated
sufficient autophagy
inhibition at 1200 mg
HCQ

Tolerated with
minor toxicities (7%
anorexia, 7% fatigue
and 7% nausea)

(191)

Advanced
Solid tumors
and
melanoma

HCQ 200 to
1200 mg daily
with doseintense oral
TMZ 150 mg/m
(2) daily

Partial response in 14%
of pts and stable
disease in 27% of
patients with metastatic
melanoma was
observed.

At 600 mg, twice
daily of HCQ,
treatment (1200 mg
HCQ) was tolerated
with Grade 2
toxicities: fatigue
(55%), anorexia
(28%), nausea
(48%), constipation
(20%), and diarrhea
(20%)

(192)

Pancreatic
Cancer

gemcitabine and
nab-paclitaxel
(1,000 mg/m2
and 125 mg/m2
combined with

Not powered enough to
detect survivor
differences, but
increased immune
infiltration and serum
biomarker responses

(193)
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600 mg, twice
daily of HCQ

detected in patients
treated with HCQ

Non-small
Paclitaxel with
Cell
Lung carboplatin, and
bevacizumab
cancer
combined with
200 or 600 mg
HCQ daily

21% of pts had stable
disease with addition of
HCQ and median PFS
was 3.7 months (3.2 to
5.8 months) for patients
taking HCQ

Grade 3 or higher:
neutropenia (35%),
anemia (15%),
thrombocytopenia
(10%) and
dehydration (10%)

(194)

EGFR-mut
NSCLC

Combination of HCQ
and Erlotinib did not
improve PFS compared
to Erlotinib alone

Grade 3 Fatigue and
nausea

(195)

1.4.

Erlotinib (150
mg/daily) with
or without HCQ
(1,000
mg/daily)

Senescence

1.4.5. General Introduction and History
Cellular senescence is a durable growth arrest induced in response to oxidative, genotoxic,
replicative, and therapeutic stress. Senescence is originally derived from the Latin word “senex”,
which means “old” and was first utilized by Hayflick and Morehead in the early 1960s (196,197).
Contrary to the paradigms of the time that cells in vitro grow indefinitely, Hayflick and Morehead,
utilizing these primary fibroblast cultures derived from embryonic tissue, discovered that cells in
culture did not have the ability to replicate infinitely, but rather the fibroblasts replicated for a
finite number and entered into a growth-arrested, or senescent state (196,197). Although losing
their capacity to proliferate, these cells still remained viable and metabolically active. This was
later described as the “Hayflick Limit”, in which telomeres, which protect chromosomal ends,
progressively shorten during replication cycles until reaching a critical length resulting in a cease
in cellular division (198).
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Senescence contributes to a number of physiological processes including wound healing and
embryonic development and has also been implicated in various aging-related diseases,
neurological disorders, and cancer (199–201). Cellular senescence is conventionally viewed as a
cell-autonomous tumor suppressor mechanism because it arrests and prevents the propagation of
cells with severely mutated DNA or at risk for malignant transformation (201,202). Senescence
cells can be identified and targeted for clearance by several elements of the immune system (203),
adding to its anti-cancer function. However, a growing body of literature now supports the notion
that senescence can also promote tumorigenesis, resulting in yet another cellular program
exhibiting a double-edged sword function in cancer development (201). Cell non-autonomous
functions of senescent cells through secretion of the senescence-associated secretory phenotype
(SASP) can promote the transformation of surrounding cells (204,205) and cause remodeling of
the extracellular matrix (ECM), ultimately promoting the spread of malignant tumor cells (206–
208).
Senescence may also present as a model of tumor dormancy (209). Damage incurred by the cells
from radiation and chemotherapy can induce senescent growth arrest as the cell attempts to repair
the damaged DNA. Radiation has been shown to induce a temporary period of growth arrest,
followed by a phase of proliferative recovery (210,211) that could theoretically contribute to
disease recurrence.

1.4.6. Senescence and Apoptosis Evasion
In response to chemotherapy and radiation, cancer cells can activate multiple cellular responses to
evade apoptotic cell death. In regard to this, senescence can be induced in response to therapy as
a mode of alternative cell fate to elude cell death, and possibly contribute to disease recurrence.
For example, senescent cells exhibit multiple epigenetic modifications, including BCL family
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promoters (212,213). Yosef et al demonstrated upregulation of Bcl-W and Bcl-XL expression, antiapoptotic proteins of the Bcl-2 protein family, in senescent human fibroblasts and showed that
inhibition of these proteins with the pan-Bcl-2 family inhibitor, ABT-737, was sufficient to remove
senescent cells (214). Furthermore, Saleh et al. demonstrate senescence induction in response to
etoposide and doxorubicin in MDA-MB-231 breast cancer cells and A549 NSCLC cells,
respectively (215). Administration of ABT-293, a Bcl-2/Bcl-XL inhibitor, increased apoptosis in
response to doxorubicin and etoposide in MDA-MB-231 and A549 cells by interfering with BclXL interaction with BAX, a pro-apoptotic protein (215). The authors were also able to show
sensitization to etoposide and doxorubicin, as well as reduced tumor burden in vivo, with the
addition of ABT-263; however, ABT-263 as a monotherapy had no significant effect on tumor
burden. These studies offer insights into the potential of senescent cells to upregulate antiapoptotic Bcl-2 family proteins as a means to evade apoptotic cell death and provide potential
novel therapeutic targets for cancer treatment.

1.4.7. Characteristics of senescence
Senescent cells present with a myriad of phenotypes, such as morphological changes (enlargement
and flattening), expression of a pH-dependent ß-galactosidase activity, secretion of chemokines
and cytokines that encompass the senescence-associated secretory phenotype (SASP), and
senescence-associated heterochromatic foci (SAHF) appearance (216–218). While senescent cells
are growth-arrested, they maintain metabolic activity and exhibit enhanced lysosomal biogenesis
(109,219,220). Of note, the Senescence-Associated β-galactosidase (SA-β-gal) enzyme, a
lysosomal enzyme that functions at low lysosomal pH ~1-2 in normal cells, demonstrates an
altered optimal pH of 6 in the lysosomes of senescent cells; moreover, this has become a key
hallmark of senescent cells and is often utilized as the basis of multiple assays screening for
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senescence (221). Aside from this functional change, senescent cells undergo several
morphological and structural changes. Senescent cells appear enlarged and have flattened
morphology due to cytoskeletal changes; moreover, some cell types may develop projections,
appearing similar to a neuron-like shape (222,223). Cells undergoing senescence also have altered
mitochondrial fusion and function, as well as increased mitochondrial mass and length (224).
Cellular senescence exhibits a number of nuclear changes, including the appearance of altered
chromatin, termed heterochromatin foci, designed to repress the expression of proliferation-related
genes and maintain the growth-arrested state (225,226). While all of these multiple features are
characteristics of senescence, senescent cells exhibit a heterogenous expression of these
phenotypes and may not present all of these features; therefore, it is necessary to demonstrate
multiple phenotypes of senescence to confirm induction.
1.4.7.1.DNA Damage, p53, and senescence
Senescence is a prolonged growth arrest generally associated with the induction of DNA damage
and consequent signaling pathways. Therapy-induced DNA damage is detected by ATM, which
phosphorylates and activates p53 (99). Activation p53 results in induction of p21Cip1 (and
sometimes p16), inhibition of cyclin-dependent kinases, dephosphorylation of retinoblastoma
(Rb), and the presumed formation of Rb-E2F complexes (227,228). Collectively, these responses
interfere with the interaction between cyclin and cyclin-dependent kinases and halt cell cycle
progression. Given that cyclin-dependent kinase inhibitors (CDKIs) can drive growth arrest,
senescent cells often upregulate key cell cycle regulators, such as p21Cip1 and p16INK4a (229,230).
Senescent growth arrest can furthermore be considered as an alternative cell fate that can be
induced to allow cells to evade apoptotic cell death (231). Luo et al showed that 6 Gy radiation did
not induce significant apoptosis in A549 and H460 cells, but rather induced a premature
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senescence indicated by increased SA-b-gal staining. Furthermore, knockdown of p53 inhibited
radiation-induced senescence, while restoration of p53 expression sensitized cells to radiation and
induced senescence (232). Studies performed by Roberson et al. demonstrated induction of
accelerated senescence in response to camptothecin, a DNA-damaging agent, in p53 null H2199
human lung cancer cells. Of interest was that these investigators were able to show that a subset
of cells had the capacity to escape the therapy-induced senescence and these cells resembled
parental cells while still exhibiting SA-b-gal activity (210).
1.4.7.2.Senescence-associated secretory phenotype
A key characteristic of senescent cells is the SASP, which encompasses a unique secretion profile
including cytokines, matrix metalloproteases (MMPs), growth factors, and several other soluble
regulators (206). A number of these factors can alter the TME or promote tumor growth.
Additionally, several of these cytokines and soluble factors participate in wound healing processes
that modulate ECM remodeling, tissue repair, surrounding cells in the TME, as well as regulate
immune infiltration (233). MMPs and other proteases help to remodel the ECM around tumor cells
and can promote tumor migration (204,234). Moreover, senescent cells secrete a number of proinflammatory cytokines and chemokines, such as interleukin-6 (IL-6) and interleukin-8 (IL-8),
which can play a role in promoting tumor growth and migration. Ortiz-Montero et al demonstrated
that when MCF-7 cells were treated with conditioned media from senescent cells, IL-6 or IL-8,
markers of endothelial-to-mesenchymal transition (EMT) were upregulated, and promoted tumor
cell migration and invasion (235). Both of these inflammatory factors can modulate the activation
of the NF-kB pathway, resulting in an increase in transcription of anti-apoptotic proteins and
promote tumor growth (236). In contrast, secretion of pro-inflammatory cytokines can promote
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immune infiltration, and depending on the type of immune infiltrates, can promote or inhibit tumor
growth. Studies by Meng et al utilized radiation and the PARP inhibitor, veliparib, to promote
premature senescence in B16SIY melanoma cells (237). When these senescent cells were isolated
and injected into C57BL/6 mice, a number of cytokines were upregulated and an increase in CD8+
T cell proliferation was observed in coculture studies. Furthermore, vaccination of tumor-bearing
mice with senescent cells followed by subsequent radiation was sufficient to elicit immune
responses and eliminate established tumors. As exemplified, cellular senescence can play a dual
role in tumor development itself, and a verdict on whether these soluble factors produced by
senescent cells promote or antagonize tumorigenesis has yet to be achieved (238).

1.4.8. Senescence in response to therapy
1.4.8.1.DNA Damaging Agents
A number of cytotoxic cancer therapies have been shown to induce senescence in multiple different
cancer cell types (239). Previous studies have quite conclusively demonstrated growth arrest,
characteristic of senescence, in response to radiation therapy and DNA-damaging agents (240–
244). Cui et al showed that treatment with 4 Gy radiation in cervical cancer cells induced only
16% apoptosis but did induce a long-lasting G2/M phase arrest (245). Cisplatin, a DNA-alkylating
agent, was shown to induce senescence in nasopharyngeal carcinoma and ovarian cell lines
through p53 and cdc2 induction (246,247). Etoposide, a topoisomerase II inhibitor, induced
senescence in HepG2 hepatocarcinoma and U2OS osteosarcoma cells as exhibited by increased
SA-ß-gal activity and p53/p21 protein levels (248). Moreover, doxorubicin, an anthracycline
antibiotic, mediates its anti-tumor effects by intercalating DNA base pairs, as well as inhibiting
topoisomerase II, causing DNA strand breaks and blocking both DNA and RNA synthesis
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(249,250). Doxorubicin has been shown to induce senescence in breast, NSCLC, colorectal cancer
(251–254). Taken together, several chemotherapies inducing DNA damage through varying means
seem to activate senescent programming in response to damage.
1.4.8.2.Non-DNA damaging Agents
While DNA-damaging agents are more often associated with senescence induction due to their
mechanism of action, various cytotoxic cancer therapies not directly associated with causing DNA
damage have also been shown to induce senescence (239). For example, methotrexate, an
antimetabolite that inhibits tetrahydrofolate synthesis, was shown to activate a premature
senescence through p53 acetylation in C85 human colon cancer cells (255). Paclitaxel is a
microtubule poison that stabilizes tubulin and prevents its depolymerization, ultimately disrupting
cell division (256). Exposure to paclitaxel was shown to induce senescence in bladder cancer and
breast cancer (257,258). Furthermore, hormonal deprivation therapy, such as anti-estrogens and
anti-androgen therapy, demonstrated senescence induction in breast and prostate cancer models,
indicating activation of the senescent phenotype is not reliant on genotoxic stress (259–261).
Palbociclib, a CDK4/6 inhibitor, has become a front-line treatment for advanced metastatic
estrogen-positive breast cancer patients who developed resistance to prior anti-estrogen therapy
(262). Palbociclib works much like a traditional CDKI, such as p21 and p16, by interfering with
the interaction between CDK4/6 and cyclin D, resulting in a cell cycle halt (262,263). Palbociclib
was also shown to induce both autophagy and senescence in gastric cells and breast cancer cells
(264,265).
While several pre-clinical models demonstrate senescence induction in response to a multitude of
chemotherapies, radiation, and target therapies (261,265–270), activation of senescence in patient
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tumors is poorly understood. Thus, further inquiry and advanced screening techniques are required
to enhance our comprehension of patient tumor responses to anti-cancer therapy.

1.4.9. Clinical Implications of Senescence: Utilization of Senolytics
One limitation to efforts to fully understand the role and contributions of therapy-induced
senescence in sensitivity to radiation is the absence of specific pharmacologic or genetic
approaches to silence the senescence response. Nevertheless, our recent evidence of
outgrowth/escape from senescence (271) argues for the likelihood that senescence, like autophagy,
maybe a cytoprotective response that allows the tumor cells to escape elimination by radiation and
chemotherapy. The prolonged and sustained growth inhibition may be permissive for the ultimate
regrowth of the tumor cells and the consequent disease recurrence. Given this possibility, coupled
with evidence that the SASP may also promote tumor growth, the recent identification of agents
with “senolytic” properties, which promote apoptosis selectively in senescence cells opens the
possibility of developing a therapeutic strategy for elimination of the residual surviving tumor cells
(272,273).
Work by Yosef and colleagues demonstrated that human fibroblasts induced into senescence by
radiation upregulated anti-apoptotic proteins, Bcl-W and Bcl-XL in vivo. Targeting these proteins
using a small-molecule inhibitor, ABT-737, was sufficient to eliminate these senescent cells (214).
Similarly, Samaraweera et al. showed senescence induction and SASP secretion in both NSCLC
cells and head and neck squamous cell carcinoma (HNSCC) cells when exposed to cisplatin or
taxanes. Furthermore, administration of Panobinostat, an FDA-approved HDAC inhibitor,
following chemotherapy exposure suppressed proliferation and induced cell death in both cancer
cell types (274). While many agents have been proposed to have senolytic properties (272,275),
not all of these compounds are universally effective; consequently, further work will be required
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to generate clearer insights as to exactly how these agents act as “senolytics” and why particular
agents are effective under certain experimental conditions but not others. Taken together,
selectively targeting senescent cells while they are dormant and before they begin to regain
proliferative recovery may serve as a therapeutic benefit and prolong patient survival, as well as
increasing the delay before disease recurrence.

In response to chemotherapy and radiation, tumor cells can undergo a number of cell fates and
processes. While apoptosis is the desired outcome of clinical treatment, tumor cells can often
activate various survival mechanisms, such as autophagy and senescence, in hopes to evade
apoptotic cell death. It is, therefore, necessary to examine the contributions and function of these
alternative cell fates on tumor cell sensitivity to anti-cancer therapy. The studies presented in this
dissertation were designed to examine the cellular response of autophagy in radiation and cisplatin
exposure, individually, in NSCLC cell lines, as well as the effects of p53 status on these responses.
An additional goal was to determine whether autophagy could be modulated to sensitize tumor
cells to therapy and to assess the contribution of nonprotective autophagy towards senescence
induction.
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Chapter Two: What are the cellular responses and the effect of p53
status on radiosensitivity in H460 NSCLC cells?
2.1 Introduction
Radiotherapy
Radiation is an important pillar of cancer therapeutics, exerting its anti-tumor DNA-damaging
effects through various direct and indirect mechanisms. The effects of radiation are largely
mediated through DNA damage that is both direct and indirect, the latter via free radical generation
(276). Thus, the efficacy of radiation is partly dependent on the oxygenation of tumors, which is
required to generate ROS and incur damage (277). While cells respond with compensatory
mechanisms by antioxidants, such as glutathione and superoxide dismutase (SOD), localization of
radiation-induced damage increases ROS levels, tipping redox equilibrium, and ultimately
resulting in cell death (278). The impact of radiation-induced damage tends to be delayed,
occurring over several cell cycles, resulting in aberrant chromosomes and compromised DNA
integrity. Long-term damage to normal cells/tissue at the tumor periphery remains a key issue
when injury accumulates in critical organs. The nature of the tumor cell response to radiation can
vary. Radiation-induced DNA strand breaks activate a multitude of DNA damage response
processes to prevent the propagation of cells carrying the mutated/damaged DNA. Radiation has
served as an effective mode of treatment for a number of cancer types, for both curative and
palliative treatment; however, resistance to therapy still remains a prevalent issue.
Although tumor cell apoptosis is the desired outcome for radiation and cytotoxic therapy, it is
often not the sole or obligatory response to therapy. Tumor cells can activate multiple pathways,
such as autophagy or senescence, in attempts to evade cell death pathways, which may contribute
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to disease reoccurrence or poor patient response to therapy. Autophagy is induced as a “first
responder”, aiding to prevent damage accumulation. Cellular stress, metabolic dysregulation, and
oxidative stress can have detrimental effects on protein oxidative states, genome stability, and
mitochondrial energetics (279). In order to reduce the burden of the damage, autophagy is induced
to alleviate stress by aiding in the turnover of damaged proteins and organelles (280). While
hypoxia- and starvation-induced autophagy represent largely cytoprotective responses (281,282),
the role(s) of chemotherapy- and radiation-induced autophagy are less clear (117). The
cytoprotective function of autophagy is often thought to reflect efforts by the tumor cell to prevent
the cell from undergoing apoptosis and prolong survival (104,126). However, there are also
extensive examples of studies where inhibition of autophagy fails to sensitize the tumor cells to
the initiating stress (141,283,284) which we have termed “non-protective autophagy” (117,285).
The relevance and potential clinical importance of the non-protective form of autophagy relate to
efforts to sensitize malignancies to therapy through autophagy inhibition. That is unless the
autophagy induced in the clinic is cytoprotective in function, there is unlikely to be a therapeutic
advantage to its inhibition.
Literature evidence also demonstrates the functional autophagic response is not always consistent
in tumor cells exposed to radiotherapy (141). Further analyzing these studies by Schaaf et al.,
pharmacological inhibition with CQ and 3MA did not alter radiosensitivity in MDA-MB-231
breast tumor cells when exposed to 5.6 Gy; however, work done by Chaachouay et al. showed
that autophagy inhibition with similar concentrations of CQ and 3MA was sufficient to
radiosensitize the same MDA-MB231 cell line exposed up to 5 Gy radiation (92,145). These
contradictory observations present a conundrum within the field when the same cell line, exposed
to similar doses of radiation and concentrations of the autophagy inhibitor, can produce two
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divergent responses, leading to opposing conclusions relating to the role of autophagy. Thus, the
nature of autophagy in response to radiotherapy and mediators regulating autophagic function
warrant further interrogation.
Alongside autophagy, recent studies have demonstrated that radiation can also induce a cellular
growth arrest characteristic of senescence. Senescence is an alternative cell fate that can be induced
to allow cells to evade cell death by halting cell cycle progression (286). Radiation-induced DNA
damage can result in a cellular senescence as the cell attempts to repair the damaged DNA;
however, depending on the extent of damage, cells can undergo cell death if the damage is too
great or repair the damaged DNA and allow a subset of senescent cells to regain proliferative
capacity (287,288). p53, an essential tumor suppressor, is a central player in regulating apoptosis,
autophagy, and senescence, and tumor cells with loss or mutated p53 have been shown to exhibit
reduced susceptibility to radiation-induced apoptosis (289–291). Therefore, utilizing H460 p53
wild type expressing cells (H460wt) and H460 cells with a p53 knockout generated through
CRISPR/CAS9 technologies (H460crp53), we further examined the effects of p53 status on tumor
cell responses and sensitivity to radiotherapy.
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2.2. Methods
2.2.1. Antibodies and reagents
The following primary antibodies were used: SQSTM1/p62 (BD Biosciences, 610497); ATG5
(Cell Signaling Technology, 2630); LC3B (Cell Signaling Technology, 3868); TP53 (BD
Biosciences, 554293); GAPDH (Cell Signaling Technology, 2118). Secondary antibodies:
Horseradish peroxidase (HRP)-conjugated secondary antibodies (Cell Signaling, anti-mouse,
7076S; anti-rabbit, 7074S), and TRITC-conjugated secondary antibodies (Invitrogen, A21424)
or FITC-conjugated secondary antibodies (Invitrogen, A11070). Hoechst 33258 was purchased
from Thermo Fisher Scientific (H3569).

2.2.2. Cell Lines
H460 cells were acquired from ATCC (NCI-H460). p53 knockout H460 cells were generated by
co-transfection (3x106 cells in 10 cm dish) with 1 μg CRISPR-Cas9 plasmid targeting the p53 loci
(Santa Cruz Biotechnologies; cat #sc-416469) and 1 μg of a homology directed repair plasmid for
p53 (Santa Cruz, cat. #sc-416469-HDR). Cells were transfected using PolyJet reagent (Signagen)
following the manufacturers guidelines. After 72 hours, cells were exposed to 2.5 μg/ml puromycin
with daily media exchanges to replenish selection agent. After all cells transfected with 1 μg of a
control CRISPR/Cas9 plasmid (Santa Cruz Biotechnologies cat#sc-418922) were killed (~96 h),
puromycin was removed and the cells allowed to recover and grow as individual colonies, which
were then selected and examined for expression of p53 by western blotting.
The ATG5-knockdown was generated as follows: Mission shRNA bacterial stocks for ATG5
were purchased from Sigma Aldrich. Lentiviruses were produced in HEK 293T cells cotransfected using EndoFectinTM Lenti Transfection Reagent (GeneCopoeia, 1001-01) with a
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packaging mixture of psPAX2 and pMD2.G constructs (Addgene). Media containing the viruses
was used to infect the H460 cells; puromycin (1 μg/ml) was used as a selection marker to enrich
for the infected cells.

2.2.3. Cell Culture and Treatment
H460wt and H460crp53 NSCLC cells were cultured in DMEM media supplemented with 10%
(v/v) fetal bovine serum (Thermo Scientific), 100 U/ml penicillin G sodium (Invitrogen), and 100
μg/ml streptomycin sulfate (Invitrogen). Puromycin (1 μg/ml; Sigma) was used to maintain the
selection of shATG5 and shControl transfected cells. Cells were incubated at 37℃ under
humidified 5% CO2.
Cells were seeded on day 0 followed by irradiation (0,2,4,6, or 8 Gy) on day 1 utilizing a
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irradiator. Media was replenished every other day.

2.2.4. Cell Viability Assay
For cell viability assessed by trypan blue exclusion, cells were plated in 6-well plates at a density
of 50,000 cells per well and pre-treated with 3MA (0 or 1 mM), CQ (0 or 10 µM), or Baf A1 (0 or
5 nM) 3 h prior to irradiation (0,2,4,6, or 8 Gy). Media was replenished 24 h post-radiation. Cells
were trypsinized, stained with 0.4% trypan blue (Sigma, T01282), and counted on the indicated
days using a hemocytometer. Cellular growth curves were generated from the collected data.

2.2.5. Assessment of Apoptosis
The extent of apoptosis was monitored by Annexin V-FITC and Propidium Iodide staining. Cells
were pre-treated with 3MA (0 or 1 mM), CQ (0 or 10 µM), or Baf A1 (0 or 5 nM) 3 h prior to
irradiation (0,2,4,6, or 8 Gy). Media was replenished 24 h post-radiation. On the day of analysis,
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cells were trypsinized, washed with 1X PBS and stained according to manufacturer protocol
(Annexin V-FITC Apoptosis Detection Kit; BD Biosciences, 556547). Fluorescence was
measured using flow cytometry using BD FACSCanto II and BD FACSDiva software at the Flow
Cytometry Core Facility at Virginia Commonwealth University. For all flow cytometry
experiments, 10,000 cells per replicate were analyzed and three replicates for each condition were
analyzed per independent experiment.

2.2.6. Determination of Acidic Vesicle formation through Acridine Orange Staining
Cells were plated in 6-well plates at a density of 50,000 cells per well and pre-treated with 3MA
(0 or 1 mM), CQ (0 or 10 µM), or Baf A1 (0 or 5 nM) 3 h prior to irradiation (0,2,4,6, or 8 Gy).
Media was replenished 24 h post-radiation. Cells were stained with 1 μg/ml acridine orange at 37
℃ for 15 min and then washed with PBS. Cells were imaged using an inverted fluorescence
microscope (Olympus, Tokyo, Japan). For quantification of autophagic vesicles (AVOs), cells
were trypsinized, harvested and washed with PBS. Pellet fractions were resuspended in PBS and
analyzed by BD FACSCanto II and BD FACSDiva software. All experimental procedures were
performed with cells protected from light.

2.2.7. LC3/LAMP2 Co-localization
For immunofluorescence staining, cells were treated with 6 Gy radiation and staining was
performed 72 h post-radiation. Cells were fixed with 100% methanol for 15 min, permeabilized
with 0.1% Triton X-100 for 15 min, and then blocked with 5% bovine serum albumin (BSA).
Cells were incubated with primary antibody (1:100) overnight at 4°C, and then exposed to FITCor TRITC-conjugated secondary antibody for 2 h at room temperature. Finally, nuclei were
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stained by Hoechst 33258. Immunofluorescence was detected by inverted fluorescence
microscopy (Olympus, Tokyo, Japan).

2.2.8. Western Blot Analysis
After indicated treatments, cells were trypsinized, harvested, and washed with 1X PBS. Pellets
were lysed with CHAPS buffer (Thermo Scientific) containing protease inhibitor (Sigma, P8340)
and phosphatase inhibitor Sigma, P576). Protein concentrations were determined by the Bradford
Assay (Bio-Rad Laboratories, 5000205 Total protein was diluted in sample buffer and boiled for
15 minutes prior to loading. Protein samples were loaded and subjected to SDS-polyacrylamide
gel electrophoresis, transferred to polyvinylidene difluoride membrane, and blocked with 5%
milk in 1X PBS with 0.1% Tween 20 (Fisher, BP337). Membrane was incubated overnight at
4°C with indicated primary antibodies at a dilution of 1:1000 in 5% BSA. The membrane was
then washed with 1X PBS with 0.1% Tween 20 three times and secondary antibody was added at
a dilution of 1:2000 in 5% BSA for 2 h at room temperature. The membrane was washed again
with 1X PBS with 0.1% Tween 20 three times. Blots were developed using Pierce enhanced
chemiluminescence reagents (Thermo Scientific, 32132) on BioRad ChemiDoc System.
Densitometry analysis of the western blots was performed using NIH software Image J2. Except
in the case of LC3, all protein band densities were normalized for their corresponding GAPDH
loading control band densities.

2.2.9. β-galactosidase and C12FDG staining
Cells were plated in 6-well plates at a density of 50,000 cells per well and treated with irradiation
(0,2,4,6, or 8 Gy). Media was replenished 24 h post-radiation. β-galactosidase staining was
utilized to qualitatively visualize senescent cells. Staining was performed as previously described
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by Dimri et al. (292). Phase contrast images were taken using an inverted microscope (Olympus,
Tokyo, Japan).
To quantify ß-gal positive senescent cells, after irradiation, cells were treated with Bafilomycin
A1 (100 nM) for 1 h to achieve lysosomal alkalinization, followed by staining with C12FDG (10
μM) for 2 h at 37 ℃. After incubation, cells were collected and analyzed by BD FACSCanto II
and BD FACSDiva software. All experimental procedures were performed with cells protected
from light.

2.2.10. Extent of DNA Damage
Cells were seeded in 6-well plates and incubated overnight. After exposure to the indicated treatment, cells
were fixed with 70% ethanol for 15 minutes and then blocked with 5% bovine serum albumin (BSA). Cells
were incubated with gH2AX antibody (1:1000; BD Pharmagen, 560445) for 2 h, and fluorescence was
quantified using flow cytometry. For quantification of DNA damage, cells were trypsinized, harvested and
washed with PBS. Pellet fractions were resuspended in PBS and analyzed by BD FACSCanto II and BD
FACSDiva software. All experimental procedures were performed with cells protected from light.

2.2.11. Statistical analysis
GraphPad Prism 5.0 software was utilized to conduct statistical analysis. Data are shown as mean
± SD from at least three separate experiments, unless indicated otherwise. Statistical comparisons
between groups were assessed via one-way ANOVA followed by Bonferroni post-hoc test and
two-tailed t tests; p-value < 0.05 was considered statistically significant.
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2.3. Results

2.3.1. Radiation Sensitivity in p53 Wild-type and p53 Knockout H460 cells
Mutations to p53 or loss of p53, an essential tumor suppressor gene, have been reported in more
than 50% of tumor cell types, including lung, breast, colon, and many others (16,293). The status
of p53 and its contributions to radiation sensitivity has become an area of important interest over
the years; however, the mechanisms underlying the effect of p53 status on radiosensitivity and
resistance to therapy still remains elusive. To further interrogate this question, we utilized p53
wild-type H460 NSCLC cells and H460 cells with a p53 knockout generated through
CRISPR/CAS9 gene-editing (Figure 2.1A). Radiation sensitivity was assessed in both cell lines
through analysis of cell viability over time using trypan blue exclusion. Temporal analysis of
radiosensitivity demonstrated that H460wt cells were significantly more sensitive than H460crp53
cells (Figure 2.1B). Furthermore, H460wt cells exhibited growth arrest in response to 6 Gy
radiation exposure while H460crp53 underwent a lesser degree of growth inhibition and continued
to proliferate.
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Figure 2.1. Sensitivity to ionizing radiation (IR) in H460wt and H460crp53 NSCLC cells.
A. Western blot analysis. B. Temporal analysis of cell viability. Cells were exposed to 6 Gy
radiation, incubated with fresh medium for the indicated number of days and viable cell number
determined by trypan blue exclusion. Results were from three independent experiments. *p < 0.05,
radiation exposure in H460wt cells versus H460crp53 cells.
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2.3.2. Radiation induced apoptosis in H460wt and H460crp53 cells.
In response to radiotherapy, H460wt and H460crp53 cells exhibited differential sensitivity.
Previous literature has suggested loss of functional p53 can reduce cellular susceptibility to
apoptotic cell death (291,294). To further inquire whether the differences in sensitivity were a
result of cell death, we examined the extent of apoptosis induced in response to radiation in both
of these cell lines. Cells were exposed to varying doses of radiation and the extent of apoptosis
was measured through Annexin V/PI staining. The fluorescence was quantified using flow
cytometry. Figure 2.2A demonstrates the extent of apoptosis in both cell lines was relatively low
and induced to similar extents in both H460wt and H460crp53 cells in a dose-response study of
radiation-induced apoptosis. Further examining the induction of apoptosis over time, cells were
exposed to 6 Gy radiation and radiation-induced apoptosis was assessed on the indicated days.
Radiation did moderately increase apoptotic cell death, falling in between ~15-25% with 72 h postradiation exposure; however, consistent with the dose-response study, the extent of apoptosis was
similar in both H460wt and H460crp53 cells (Figure 2.2B). Taken together, these data indicate,
the differential sensitivity exhibited between H460wt and H460crp53 cells was not a result of
differences in the extent of apoptosis induced by radiation.
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Figure 2.2. Radiation induced apoptosis in H460wt and H460crp53 cells to a similar extent.
A. Apoptosis Dose Response. After exposure to the indicated doses of radiation, cells were
incubated with fresh medium for 2 days, and apoptotic cells identified by Annexin V/PI staining
and flow cytometry. B. Apoptosis Time Course. After exposure to 6 Gy radiation, apoptotic
cells were identified by Annexin V/PI staining and flow cytometry at the indicated days. Results
were from three independent experiments. *p < 0.05, radiation exposure in H460wt cells versus
H460crp53 cells.
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2.3.3. Radiation induced autophagy in both H460wt and H460crp53 cell
Extensive literature evidence indicates that autophagy is often induced in response to radiationinduced damage (91,92). Consequently, we examined autophagy induction in response to radiation
exposure in both cell lines, utilizing acridine orange to demonstrate acidic vesicle formation as an
initial screen. While acridine orange is not a specific indicator of early autophagosome formation,
it can be utilized as an indication for later stages of autophagy, as the autophagosome fuses with
lysosomes to form acidic vacuoles termed “autolysosomes” (295). An increase in acidic vacuole
formation was demonstrated 72 h post-6 Gy radiation exposure in both H460wt and H460crp53
cells (Figure 2.3A). A dose-response in acridine orange fluorescence was further quantified using
flow cytometry. Dose-dependent acidic vesicle formation was exhibited in both H460wt and
H460crp53 cells 72 h post-radiation exposure; however, acridine orange fluorescence was greater
in H460wt cells compared to H460crp53 cells (Figure 2.3B). To further confirm autophagy
induction, western blot analysis was utilized to determine lipidation of LC3 (LC3 I to LC3 II
conversion) and degradation of p62/SQSTM1 protein levels. Figure 3C demonstrates autophagic
induction and autophagic flux (i.e., autophagy going to completion) in both cell lines, as indicated
by LC3 I-II conversion and p62 protein degradation in both H460wt and H460crp53 cells exposed
to 6 Gy radiation. Interestingly, p62 degradation occurs on Day 4 in H460crp53 cells compared to
H460wt cells where significant p62 degradation is evident on Day 1, suggesting that autophagy
may be delayed in H460crp53 cells. The difference in the rate of autophagic flux between the two
cell lines may contribute to differences seen in the acridine orange quantification since the acridine
orange studies were performed on Day 3. Finally, Figure 2.3C demonstrates co-localization of
LC3 (green), an autophagosome marker, to LAMP-2 (red), a lysosomal marker, indicating fusion
(yellow) of autophagosomes with lysosomes in the final steps of autophagy completion. In
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response to 6 Gy radiation exposure, both H460wt and H460crp53 cells exhibited increased LC3
(green) fluorescence, indicating autophagy induction. Furthermore, merging of LC3 and LAMP-2
demonstrated the formation of autolysosomes (yellow) in both H460wt and H460crp53 cells 72 h
post-IR exposure, indicating autophagy was going to completion. Interestingly, untreated
H460crp53 exhibited higher LC3 immunofluorescence compared to H460wt cells, suggesting
basal autophagy was higher in H460crp53 cells compared to their p53 wt counterpart. Collectively,
these data indicate autophagy was induced and autophagic flux was occurring in response IR
exposure in both H460wt and H460crp53 cells, and autophagic that flux is delayed in H460crp53
cells.

56

Figure 2.3. Radiation-induced autophagy in H460wt and H460crpp53 NSCLC cells.
A. Acridine orange staining. Three days after exposure to 6 Gy radiation, cells were stained
with acridine orange; images were taken at the identical magnification (scale bar = 200 μm, n =
2). B. Quantification of acridine orange staining. Autophagy was quantified based on acridine
orange staining as measured by flow cytometry. C. Western blotting for levels of relevant
proteins. The status of p53 in both H460 cell lines was confirmed by western blotting. Autophagy
was assessed based on p62/SQSTM1 degradation and the conversion of LC3 I to LC3 II. The bar
graph in each panel indicates the relative band intensity generated from densitometric scans of
three independent experiments in arbitrary densitometric units. D. Co-localization of LC3 and
LAMP. Fluorescence microscopy showing LC3 and LAMP2 co-localization in response to 6 Gy
radiation. Imaging was performed 3 days after radiation exposure (scale bar = 20 μm, n = 2).
Unless stated, otherwise data were from three independent experiments. *p < 0.05, control cells
versus irradiated cells.
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2.3.4. Nonprotective autophagy induced in response to radiotherapy in H460wt and
H460crp53 cells
In response to chemotherapy and radiation, autophagy is often thought to elicit its conventional
cytoprotective function in order to remove damaged organelles and proteins and prevent toxic
accumulation (296,297). While autophagy can play a cytoprotective function in response to anticancer therapy, autophagy can also be multifunctional in its role. Therefore, we interrogated the
functional role of autophagy in response to radiotherapy to identify whether functional differences
in autophagy contributed to the differential radiosensitivity exhibited between H460wt and
H460crp53 cells. The pharmacological autophagy inhibitor, 3-methyadenine (3-MA), was utilized
to examine the effects of autophagy inhibition on radiosensitivity of these two isogenic cell lines.
3-MA is a class III PI3K inhibitor, which is essential for induction and initiation of autophagosome
formation (153). To ensure autophagy was sufficiently inhibited, acridine orange staining and
western blot analysis was utilized. Cells were pre-treated with 3-MA (1 mM) for 3 h followed by
6 Gy IR and stained with acridine orange or protein lysates were collected 72 h post-radiation for
Western blotting. Figure 2.4A demonstrated reduced acidic vacuoles when cells were exposed to
3-MA prior to IR treatment in both H460 and H460crp53 cells. Furthermore, autophagy inhibition
with 3-MA was confirmed through western blot analysis. Figure 2.4B shows that administration
of 3-MA in H460wt and H460crp53 cells resulted in a reduced LC3 II/I conversion ratio,
suggesting 3-MA in combination with radiation was sufficient to inhibit autophagy in both cell
lines. Next, the effects of pharmacological inhibition of autophagy on radiosensitivity in H460wt
and H460crp53 cells were examined. Cells were pre-treated with 3-MA (1 mM) for 3 h followed
by 6 Gy radiation. Autophagy inhibition through 3-MA exposure prior to 6 Gy IR did not
significantly alter sensitivity to radiation when examining cell viability over time in both of these
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cell lines and did not interfere with radiation-induced cell death (Figure 2.4C-D). Taken together,
pharmacological autophagy inhibition did not significantly alter radiosensitivity or radiationinduced cell death in H460wt and H460crp53 cells, indicating that autophagy was nonprotective
in function in response to radiation.
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Figure 2.4. 3-MA fails to alter radiation sensitivity in H460wt or H460crp53 NSCLC cells.
A. Inhibition of autophagy by 3-MA. Western blot showing autophagy blockade by 3-MA (1
mM) based on levels of LC3 II. Cells were pretreated with 3-MA for 3 h prior to radiation and
protein was collected three days after irradiation. The bar graph in each panel indicates the relative
band intensity generated from densitometric scans of two independent experiments in arbitrary
densitometric units. B. Inhibition of autophagy by 3-MA. Cells were pretreated with 3-MA for
3 h prior to radiation and cells were stained with acridine orange three days after irradiation (scale
bar = 200 μm, n = 2). C. Influence of 3-MA on radiation sensitivity. Cell viability assay
indicating that 3-MA has no effect on radiosensitivity in either H460wt or H460crp53 cells. Cells
were pretreated with 3-MA for 3 h followed by radiation. D. Influence of 3-MA on radiation
induced apoptosis. Annexin V/PI staining showing that 3-MA has no effect on radiation induced
apoptosis in either cell line. Cells were pretreated with 3-MA for 3 h prior to radiation and
apoptosis was assessed after 2 post-treatment. Unless stated, otherwise data were from three
independent experiments. *p < 0.05, radiation treated vs radiation + 3-MA treated.
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CQ is a late-stage autophagy inhibitor, which accumulates within lysosomes and increases
lysosomal pH and prevents fusion of the autophagosome to the lysosome (149). Figure 2.5A
demonstrated lysosomal alkalization (yellow puncta in basic conditions rather than orange/red
puncta in acidic conditions) when cells were exposed to CQ prior to IR treatment in both H460
and H460crp53 cells. Furthermore, autophagy inhibition with CQ was confirmed through western
blot analysis. Figure 2.5B shows administration of CQ in H460wt and H460crp53 cells resulted
in an increase accumulation of LC3 II/I ratio and prevented p62 protein degradation, suggesting
CQ in combination with radiation was sufficient to inhibit autophagic flux in both cell lines. Next,
the effects of pharmacological inhibition of autophagy on radiosensitivity in H460wt and
H460crp53 cells were examined. Cells were pre-treated with CQ (10 µM) for 3 h followed by
varying doses of radiation, colonies were allowed to form, and the number of colonies were
counted. Figure 2.5C shows that CQ sensitized the H460wt cells to radiation while failing to
influence radiation sensitivity in the H460crp53 cells. Figure 2.5D presents a temporal analysis
of cell viability in both cell lines, confirming that the combination of 6 Gy radiation and CQ
enhanced growth inhibition in the H460wt cells, but not in the H460crp53 cells. Furthermore,
annexin V/PI staining showed that CQ significantly (but modestly) increased radiation-induced
apoptosis (from ~ 24% to 37%) in the H460wt cells but did not alter apoptosis in the H460crp53
cells (Figure 2.5E). Taken together, CQ inhibition of radiation-induced autophagy suggests that
autophagy provides a modest (albeit statistically significant) survival advantage to cells with
functional p53, which is however inconsistent with the more pronounced radiation sensitivity
evident in the H460wt cells.
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Figure 2.5. Influence of chloroquine (CQ) on radiation sensitivity in H460wt and H460crp53
cells.
A. Inhibition of autophagy by CQ. Fluorescence microscopy showing acridine orange-stained
vacuoles induced by 6 Gy radiation alone or with CQ (10 μM) treatment (scale bar = 200 μm). B.
Inhibition of autophagy by CQ. Western blot showing autophagy blockade by CQ (10 μM) based
on levels of p62/SQSTMQ and LC3 II. Cells were pretreated with CQ for 3 h prior to irradiation
and protein was isolated after 3 days. The bar graph in each panel indicates the relative band
intensity generated from densitometric scans of three independent experiments in arbitrary
densitometric units. C. Influence of autophagy inhibition on radiation sensitivity. Cell viability
assay indicating that CQ increased sensitivity of H460wt cells to radiation (6 Gy), but not
H460crp53 cells. D. Influence of autophagy inhibition on radiation induced apoptosis.
Annexin V/PI staining indicating that CQ (10 μM) increased radiation-induced apoptosis (after 2
days) in H460wt cells, but not in H460crp53 cells. Results were from three independent
experiments. *p < 0.05, radiation treated cells vs cells treated with radiation + CQ.
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Further, these data conflicted with the findings of the early-stage pharmacological inhibition data
in H460wt cells, which demonstrated lack of radiosensitization in both H460wt and H460crp53
cells when 3MA was administered. One possibility to the differences exhibited in autophagic
function in H460wt cells is that the autophagy was not actually cytoprotective and that the
sensitization observed in the H460wt cells might have been due to off-target effects of the
chloroquine, as has been proposed by the Thorburn laboratories (298). Finally, to confirm these
findings when late stage autophagy is inhibited, we used bafilomycin A1, which disrupts
autophagic flux by inhibiting V-ATPase-dependent decrease in lysosomal pH and, thus,
autophagosome-lysosome fusion (150). Bafilomycin A1 interfered with the completion of
radiation-induced autophagy in H460wt cells based on failure of lysosomal acidification (Figure
2.6A) and upon p62 accumulation (Figure 2.6B). Again, in agreement with the previous
observations, bafilomycin A1 had no impact on radiation-induced growth inhibition (Figure
2.6C). These results further confirm that CQ effect in H460wt was likely non-specific, that latestage autophagy inhibition does not interfere with radiation sensitivity in this cell model, and that
autophagy plays a non-protective role in H460 cells regardless of p53 status.
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Figure 2.6. Influence of Bafilomycin A1 (Baf A1) on radiation sensitivity in H460wt cells.
A. Inhibition of autophagy by Baf A1. Fluorescence microscopy showing acridine orangestained vacuoles induced by 6 Gy radiation alone or with Baf A1 (5 nM) treatment (scale bar =
200 μm). B. Inhibition of autophagy by Baf A1. Western blot showing autophagy blockade by
Baf A1 (5 nM) based on levels of p62/SQSTMQ (n=2). Cells were pretreated with Baf A1 for 3 h
prior to irradiation and protein was isolated after 3 days. C. Influence of autophagy inhibition
on radiation sensitivity. Cells were pretreated with Baf A1 for 3 h followed by radiation. Cell
viability assay indicating that Baf A1 has no effect on radiosensitivity in H460wt cells.
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To further confirm these results, short hairpin RNA was used to knock down ATG5, an autophagyrelated gene important in proper autophagosome formation (295), in both cell lines. Figure 2.7A
demonstrates reduced ATG5-ATG12 complex protein levels in both H460wt and H460crp53 cells
where ATG5 was knocked down (shATG5 cells) compared to scrambled controls (shControl
cells). Moreover, shATG5 cells exposed to radiation in both the H460wt and H460crp53 cells
exhibited increased p62 accumulation and reduced LC3 I to II conversion compared to shControl
cells treated with 6 Gy IR, confirming that autophagy had been suppressed in both cell lines. Next,
radiosensitivity was examined in autophagy-competent and autophagy-deficient H460wt and
H460crp53 cell lines. Figure 2.7B show autophagy-deficient H460wt and H460crp53 cells did not
demonstrate altered radiosensitivity in comparison to autophagy-proficient controls when
assessing cell viability over time. Lastly, autophagy inhibition did not interfere with radiationinduced apoptosis in both cell lines (Figure 2.7C). Collectively, pharmacological and genetic
inhibition of autophagy did not alter radiosensitivity or radiation-induced cell death in H460wt and
H460crp53 cells, indicating that autophagy was nonprotective in function in both of these cell
lines. Given that autophagy was nonprotective in both H460wt and H460crp53 cells, these data
suggested that differences in autophagic function was unlikely to contribute to the differential
radiosensitivity exhibited by the two cell lines.
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Figure 2.7. Atg5 knockdown fails to alter radiation sensitivity in H460wt and H460crp53
cells.
A. ATG5 knockdown. Cells were collected three days after irradiation. Western blot showing
ATG5 knockdown in H460wt and H460crp53 cell lines; inhibition of autophagy in shAtg5
H460wt and H460crp53 cell lines is indicated by reduced conversion of LC3I to LC3II and
interference with degradation of p62/SQSTM1. The bar graph in each panel indicates the relative
band intensity generated from densitometric scans of two independent experiments in arbitrary
densitometric units. B. Lack of radiation sensitization by autophagy inhibition. Temporal
viability assay indicating that Atg5 knockdown has no effect on radiosensitivity in either H460wt
or H460crp53 cells. Cells were treated with 6 Gy radiation. C. Autophagy inhibition does not
increase the extent of radiation-induced apoptosis Annexin V/PI staining indicating that
apoptosis induced by radiation was unaltered after Atg5 knockdown in both H460wt and
H460crp53 cell lines. Unless stated, otherwise data were from three independent experiments.
*p < 0.05, shControl cells treated with radiation vs shAtg5 cells treated with radiation.
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2.3.5. Radiation induced senescence in H460wt and H460crp53 cells
Tumor cells can activate a plethora of cellular processes when exposed to chemotherapy and
radiation. p53 plays a central role in modulating various cellular responses under stressed
conditions, including autophagy and senescence. Previous literature has demonstrated that
autophagy and senescence are primary responses to radiation (91,183,299,300) and often occur in
parallel. Thus, we aimed to investigate the role of senescence induction and its contributions to the
differential sensitivity seen between H460wt and H460crp53 cells. Cells were exposed to 6 Gy
radiation and senescence-associated ß-galactosidase (SA-ß-gal) activity was assayed 72 h postradiation. Figure 2.8A demonstrates ß-galactosidase staining (blue) was qualitatively greater in
the H460wt cells compared to H460crp53 cells; furthermore, H460wt cells visually exhibited more
pronounced evidence of an enlarged, flatten morphology compared to H460crp53 cells. SA-ß-gal
activity was also monitored by flow cytometry for a more quantitative approach. SA-ß-gal was
increased in both cell lines; however, SA-ß-gal staining was significantly greater in H460wt cells
over time when compared to H460crp53 cells (Figure 2.8B). These data indicate the extent of
senescence induction was greater in H460wt cells compared to H460crp53 cells and suggested that
the differential extent of senescence induction likely was the critical factor accounting for the
differences in radiosensitivity exhibited by the two cell lines. Given limitations in the field,
specifically, the lack of availability of a specific senescence inhibitor, the precise contributions of
senescence induction towards radiosensitivity remains unclear and will require further inquiry as
we gain further insights into the mechanisms underlying therapy-induced senescence.
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Figure 2.8. Radiation induced senescence in H460wt and H460crp53 cells.
A. β-galactosidase staining and cell morphology. β-galactosidase staining indicating the
induction of senescence by radiation (6 Gy) in both cell lines (scale bar = 20 μm). B.
Quantification of senescence. C12FDG staining and flow cytometry to quantify the extent of
senescence in H460wt and H460crp53 cells. H460wt cells exhibited greater induction of
senescence than H460crp53 cells. Unless stated, otherwise data were from three independent
experiments. *p < 0.05, control vs radiation treated group.
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2.4 Discussion
Ionizing radiation triggers a spectrum of responses in tumor cells including apoptosis, necrosis,
autophagy, and senescence (301–303); however, it is not yet clear what role each of these
responses may play in tumor cell radiation sensitivity or resistance and whether the responses are
tumor-specific.
While irradiated tumor cells clearly do undergo apoptotic cell death, the extent of apoptosis tends
to be relatively low (304–306). Clinically relevant or even significantly higher doses of radiation
induced only~ 20-30% apoptosis in several experimental tumor cell lines, including breast cancer,
non-small cell lung cancer (NSCLC), and colorectal cancer (141). For instance, Rodel et al.
demonstrated relative levels of apoptosis between 12% and 27% induced in response to 8 Gy
radiation in colorectal cell lines with varying radiosensitivity (306). Similarly, Qu et al reported
~20-25% apoptotic induction in MCF-7 breast cancer cells and A549 lung cancer cells with 8 Gy
radiation (307). In agreement with these data, previous work performed in our laboratory
demonstrated low levels of apoptosis (~20%) induced in breast, lung, colorectal, and head and
neck cell lines when exposed to fractionated radiation (141). It is only when higher levels of
radiation are reached (above 10 Gy) that apoptosis becomes a more pronounced response to
radiotherapy (308). This is, of course, relevant to stereotactic radiation, wherein patients are
delivered multiple precisely focused beams of fractionated radiation to achieve higher effective
doses to the tumor while minimizing damage to surrounding tissue (309–311). With regard to
cancer treatment modalities, apoptosis or other forms of cell death are, of necessity, the desired
outcomes; however, there a number of survival mechanisms cancer cells have employed to evade
(apoptotic) cell death. Both autophagy and senescence can allow cancer cells to mitigate or perhaps
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delay the damage incurred by clinical therapeutic modalities, escape cell death, and prolong
survival.
Resistance to therapy is a primary reason for poor prognosis and treatment failure in cancer
patients. Drug resistance in tumor cells can involve multiple mechanisms, including physical
barriers, lysosomal trapping of weak bases, and upregulation of several survival pathways.
Autophagy is often a “first responder” in times of cellular stress and activated in response to
cytotoxic insult. Cytoprotective autophagy has been implicated in tumor cell resistance to therapy,
as it prevents the accumulation of toxic damage. Through modulation of ROS levels and removal
of radiation-induced damage, cytoprotective autophagy can also contribute to radioresistance.
Studies by Chen et al. showed that low-dose ionizing radiation after high-dose radiation increased
ROS levels, autophagy induction and promoted radioresistance in A549 NSCLC cells (312).
Subsequent autophagy inhibition reduced cell viability of A549 cells in response to radiotherapy,
suggesting that autophagy was functionally protective in this experimental model. Moreover,
administration of N-acetyl-L-cysteine (NAC), a known free radical scavenger, blocked autophagy
and was sufficient to suppress the induced radioresistance. These studies indicate that high levels
of ROS can promote cytoprotective autophagy in lung cancer cells and thereby contribute to
radioresistance. Ko et al also demonstrated that genetic inhibition of autophagy radiosensitizes
H460 and A549 cells in vitro; however, when moved to an in vivo model of immune-competent
mice, autophagy inhibition reduced responses to radiotherapy, indicating that autophagy may be
necessary for immune clearance of tumor cells in response to radiation (176). In contrast,
Kuwahara et al. utilized radioresistant liver cancer cell lines, which they had previously generated,
to better understand the contributions of autophagy towards radioresistance (313). These
investigators demonstrated autophagy induction in response to radiotherapy in both the parental
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HepG2 cells and in the resistant cells (HepG2-8960-R). Furthermore, exposure to rapamycin, an
mTOR inhibitor and autophagy inducer, sensitized HepG2-8960-R cells to radiation (10 Gy) but
not the parental cell line. Pharmacological and genetic inhibition of autophagy reduced rather than
increasing sensitivity to acute radiation exposure (2 Gy), suggesting that suppression of cytotoxic
autophagy could contribute to radioresistance. However, there is relatively limited literature
relating to the role of autophagy in acquired radiation resistance. These observations add another
layer of intricacy to the overall role and contributions of autophagy to tumor cell growth and host
immune cell modulation.
Due to its conventionally cytoprotective function, autophagy has been implicated in tumor cell
resistance to therapy (119), making it an attractive target to sensitize tumor cells to anti-cancer
therapy. However, in addition to the cytoprotective form of autophagy, there is accumulating
evidence suggesting that autophagy can contribute to or mediate drug cytotoxicity (136,313), as
well as function in a non-protective role, wherein autophagy inhibition would not alter
chemosensitivity or radiosensitivity (117). Early studies by the Rodemann group as well as others
identified cytoprotective autophagy in response to radiation in a number of experimental tumor
cell models (92,183). In comparison, we have previously identified the nonprotective function of
autophagy in tumor cells exposed to radiation (118,141) while other laboratories have
demonstrated nonprotective autophagy in response to chemotherapy (143).
In the current work, we attempted to address this question by using our models of radiation-induced
cytoprotective and non-protective autophagy to compare radiation sensitivity, based on the
premise that tumor cells in which autophagy is cytoprotective would be expected to be significantly
less sensitive to radiation than tumor cells in which the autophagy did not exhibit the cytoprotective
function. Unexpectedly, only CQ treatment increased the radiosensitivity of the H460wt cells,
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whereas 3-MA, bafilomycin A1 and genetic autophagy inhibition showed no effect on
radiosensitivity in either cell line, raising further reservations as to the utilization of chloroquine
as an autophagic inhibitor in the experimental discernment of the nature of autophagy. This finding
supports the studies by Maycotte et al. that suggested chemosensitization by CQ could occur
independently of autophagy inhibition (298). Qu et al. demonstrated CQ administration, but not
3-MA exposure, in combination with cisplatin increased intracellular hydroxyl radicals in
cholangiocarcinoma cells through disruption of lysosomal permeability and mitochondrial
bioenergetics (314). Additionally, other laboratories have shown chloroquine may induce
apoptosis via p53-dependent pathways leading to increased apoptosis, as well as accentuating
mitochondrial fragmentation and dysfunction in already damaged mitochondria, an effect evident
in irradiated cells (314–316). Given literature evidence and lack of radiosensitization with added
models of autophagy inhibition, we concluded radiosensitivity exhibited by CQ was most likely a
result of off-target or autophagy-independent effects. Despite modest sensitization to radiation in
p53 wt cells exposed to chloroquine, the autophagy proved to be nonprotective in both cell lines
in multiple additional pharmacological and genetic inhibition models. Nevertheless, the autophagy
was far more extensive in the p53 wild-type cells than in the p53 null cells and this did not result
in protection from radiation. In fact, the p53 wild-type cells were more radiation-sensitive than the
cells lacking functional p53, thus supporting the argument that the promotion of autophagy does
not uniformly translate to reduced radiation sensitivity.
The major findings in these studies further complicate the role of p53 in radiation sensitivity.
Previous studies demonstrate perturbation of p53 function could allow cancer cells to evade
radiation-induced apoptosis, escape cell cycle checkpoints, and continue mitotic proliferation.
For example, Hep3B2.1-7 hepatocellular cancer cells that lack p53 expression were less
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radiosensitive than HepG2 cells with a functional p53 primarily due to attenuation in apoptosis
induction (317). Similarly, Cheng et al. reported that induction of p53 expression in H1299 lung
cancer cells resulted in enhanced radiosensitivity, again due to increased apoptosis induction
(318). In the current work, H460 cells with functional p53 are also more radiosensitive than their
p53-null counterparts; however, p53 status had no significant impact on apoptosis levels in
response to radiation. Instead, our studies suggest that the difference in radiation sensitivity in the
two cell lines may be largely due to their propensity to enter into a state of senescence, as was
suggested by earlier work from our group relating to the involvement of p53 in chemotherapyinduced senescence (243).
Accumulating literature has shown that DNA-damaging events and ROS generation associated
with radiotherapy can induce a premature senescence in tumor cells (259,319,320). Senescence
activation allows tumor cells to undergo an alternative cell fate, aside from cell death, and provides
an opportunity for cells to repair and potentially recover from DNA damage while halted in a cell
cycle arrest (287). Furthermore, radiation-induced DNA damage can activate p53, resulting in
senescence (300). Luo et al showed that 6 Gy radiation did not induce significant apoptosis in
A549 and H460 cells, but rather induced a premature senescence indicated by increased SA-b-gal
staining. Furthermore, knockdown of p53 inhibited radiation-induced senescence, while
restoration of p53 expression sensitized cells to radiation and induced senescence (232). In
agreement, Widel et al have shown that induction of senescence differed in p53

+/+

and p53

-/-

HCT116 cells, where the p53-deficient cells showed a significant reduction in the expression of
senescence markers in comparison to the p53-proficients cell (321). However, in these studies p53
-/-

HCT116 cells exhibited a higher frequency of apoptosis compared to its counterpart, p53

+/+

HCT116 cells, which predominantly underwent senescence in response to irradiation. The data
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presented in our findings indicate that H460wt cells undergo senescence induction to a greater
extent than H460crp53 cells, resulting in differences in radiosensitivity.

The spectrum of

responses activated by radiation exposure adds complexity to the effects of p53 status on the
toggling of cellular processes induced in response to therapy.
As indicated above, tumor cells almost uniformly undergo autophagy in response to exogenous
forms of stress such as chemotherapy and radiation. Although the bulk of the scientific literature
tends to consider autophagy as a cytoprotective response to stress and as a mechanism of
resistance, this premise is subject to a number of reservations. One is that autophagy is not
uniformly cytoprotective; in fact, autophagy can exist in one of four functional forms, only one of
which is protective; the other forms are cytotoxic, cytostatic, and nonprotective autophagy (Figure
2.9) (117). Consequently, efforts to exploit autophagy inhibition as a therapeutic strategy for
radiosensitization (or chemosensitization) are unlikely to be successful unless all autophagic
responses to radiation, regardless of the tumor type, actually prove to be cytoprotective, which is
highly unlikely based on our preclinical studies.
An abundance of literature, including this study, demonstrates senescence induction in response
to radiotherapy. SASP secretion by these senescent cells can result in altered immune infiltration,
activate senescence in neighboring cells, and promote changes in the ECM, priming the
environment for a migratory phenotype (235). Moreover, promotion and recovery from senescence
may be a potential model for tumor dormancy (271,322). Whether senescence is activated in
response to radiation in clinical settings is not well understood and begs additional investigation.
However, given the array of cellular responses induced in reaction to radiotherapy pre-clinically
(Figure 2.9), it necessary to determine clinical patient tumor responses to further surmise whether
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administration of an autophagy inhibitor or a senolytic, an agent that selectively clears senescent
cells, may provide the more advantageous approach to radiosensitize patient tumors.
While these studies provide pre-clinical evidence that tumor cells at least undergo apoptosis,
autophagy and senescence in response to radiation, it is also necessary to consider the possibility
of additional outcomes to radiotherapy such as mitotic catastrophe, necrosis, and necroptosis.
Furthermore, the extent to which of these factors contribute to radiation sensitivity or resistance
in a particular malignancy cannot be predicted in clinical settings and is likely to vary depending
on the genetic background of the tumor (or tumor cell lines).

75

Figure 2.9. Tumor cell responses to radiotherapy.
In response to radiotherapy, tumor cells can upregulate both cell death and cell survival pathways.
Whereas apoptotic cell death is the ideal outcome for clinical therapeutic treatment, tumor cells
often enter into senescence and autophagy, largely in efforts to evade cell death. However,
radiation-induced autophagy can assume different functional roles. Induction of the cytoprotective
form of autophagy allows cells to evade apoptotic cell death and prolong survival; however,
cytotoxic autophagy can facilitate either apoptotic and/or autophagic cell death. Finally, an
alternative form of autophagy that does not appear to influence cell sensitivity to radiotherapy can
occur, termed nonprotective autophagy. Senescence often occurs in parallel with autophagy,
sharing a number of mechanistic regulators. Radiation-induced senescence allows cells to
transiently arrest in efforts to repair damage. Subsequently, tumor cells may undergo apoptotic cell
death if the extent of damage is excessive or may overcome the insult, allowing for continued
survival. Senescence may also contribute to tumor dormancy, as a subset of senescent cells endure
a prolonged growth arrest and regain proliferative capacity. Senescent cells produce a unique
secretory phenotype (SASP), allowing for manipulation of the ECM and influencing surrounding
cells in the TME. Through the release of specific cytokines and chemokines, autophagy and
senescence can play immune-modulatory effects to create either immune-promoting or immunesuppressive microenvironments, thereby contributing to overall tumor survival or clearance. Both
autophagy and senescence have cell-autonomous, as well as cell non-autonomous effects, adding
to the complexity of responses and outcomes of clinical radiotherapeutics.
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Chapter Three: What is the effect of p53 status on cisplatin sensitivity
and the nature of autophagy in NSCLC cells?
3.1 Introduction
Cisplatin is a commonly used anti-cancer therapy. It is prescribed for the treatment of a number of
cancer types, including breast cancer, lung cancer, ovarian cancer, head and neck cancers, brain
cancer, as well as many others (323). Cisplatin, like most platinum-based drugs, contains a
platinum moiety which that forms covalent platinum-DNA interactions, generating both inter-and
intrastrand crosslinks in the DNA (324). Formation of these adducts interferes with the proper
binding of transcription factors and proteins required for DNA replication and DNA transcription
for protein synthesis, ultimately resulting in cell cycle arrest and apoptosis (323). While cisplatin
is a highly effective anti-cancer therapeutic, resistance to treatment still remains a prevalent issue.
Several mechanisms have been proposed for cisplatin resistance, including drug efflux via the
multi-drug resistance pump, DNA damage repair, and inhibition of apoptosis (325). Furthermore,
in response to cisplatin treatment, it has been demonstrated that cells upregulate autophagy, a
conventionally cytoprotective mechanism, and may contribute to cisplatin resistance in tumor cells
(119).
While it is indisputable that inhibition of cytoprotective autophagy proves an advantageous avenue
for chemosensitization and radiosensitization (79,123,137), it is essential to acknowledge the
multi-functional nature of autophagy in response to therapy (139,141,313). As exemplified from
the previous studies on radiation, autophagy was nonprotective in function, regardless of p53
status, indicating autophagy inhibition failed to sensitize cells to radiotherapy (142). Furthermore,
previous work from our laboratory demonstrated the existence of an important phenomenon, which
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we have termed the “autophagic switch” where the functional form of autophagy can be changed
to another form in response to external or biological stressors. In these studies, ZR-75-1 breast
cancer cells, expressing wild type p53, exhibited cytoprotective autophagy when treated with
radiation alone; however, when given in combination with 1,25-dihydroxy vitamin D3, the
functional form of autophagy was “switched” to a cytotoxic form (326). Autophagic function may
be regulated by several factors, including p53, oxidative stress, and genotoxic stress (19,51,327).
Depending on the spatiotemporal localization of p53, it can both suppress and activate autophagy
(328). Whether p53 plays a role in determining the nature of the autophagy is not yet understood;
however, in this work, we attempt to further probe this question by utilizing a set of isogenic cell
lines, H460wt and H460crp53 NSCLC cell lines, used previously in our studies relating to
radiation.
Cisplatin-induced DNA damage can result in the activation of p53 and, depending on the amount
of damage, induce a multitude of cellular responses including senescence, autophagy, and
apoptosis (104,329). Furthermore, loss of p53 is also associated with increased tolerance to
cisplatin-induced DNA adducts and replicative bypass, contributing to cell survival and treatment
resistance (325,329). From the studies presented in chapter 2 with radiation, p53 status plays a role
in toggling between important cellular responses. In response to radiotherapy, senescence seemed
to play a predominant role in mediating the differential radiation sensitivity between H460wt and
H460crp53 cells. Similarly, senescence induction in response to cisplatin exposure has been
demonstrated in ovarian, NSCLC, and melanoma cell lines (246,330,331). Furthermore, cisplatininduced SASP secretion in senescent melanoma cells was shown to promote cellular growth in
non-senescent counterparts (330). Thus, the current study paralleled the radiation studies to
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examine the effects of p53 status on tumor cell responses to cisplatin exposure and whether the
type of cytotoxic therapy affects autophagic function.

3.2. Methods

3.2.1. Cell Culture and Treatment
H460wt and H460crp53 NSCLC cells were cultured in DMEM media supplemented with 10%
(v/v) fetal bovine serum (Thermo Scientific), 100 U/ml penicillin G sodium (Invitrogen), and 100
μg/ml streptomycin sulfate (Invitrogen). Puromycin (1 μg/ml; Sigma) was used to maintain the
selection of shATG5 and shControl transfected cells. Cells were incubated at 37℃ under
humidified 5% CO2. Cisplatin was purchased from Cayman Chemical Company (13119) and
dissolved in dimethylformamide to a stock solution of 10 mM. Working solutions were further
diluted in media.
Cells were seeded on day 0 followed by cisplatin treatment (0, 2.5, 5, 10, 20 μM) on day 1 for 24
h. Media was replenished every other day. For autophagy inhibition studies, cells were treated
with pre-treated with 3MA (0 or 1 mM) or CQ (0 or 10 µM) 3 h prior to cisplatin (0 or 10 µM)
exposure for 24 h. All assays performed as previously described.

3.3 Results

3.3.1. Cisplatin sensitivity in H460wt and H460crp53 NSCLC cells
In previous work, we reported that radiation-induced autophagy was nonprotective in the H460
non-small cell lung cancer cell line regardless of p53 status (142). In order to investigate whether
autophagy is universally nonprotective in this cell line, the current studies utilized the antitumor

79

drug, cisplatin, as the primary autophagy inducer. Furthermore, utilizing the same set of isogenic
cell lines, H460wt and H460crp53 NSCLC cells, we aimed to discern the effects of p53 status on
cisplatin sensitivity and autophagic function.
Initially, cells were exposed to 10µM cisplatin for 24 hrs. Temporal analysis of cell viability was
assessed to confirm the differential sensitivity to cisplatin. Figure 3.1A demonstrates that H460wt
cells were more sensitive to 10 µM cisplatin exposure than H460crp53 cells. Temporal response
pattern largely showed that the H460wt underwent a rapid growth decline, indicative of cell death,
while the H460crp53 cells initially continue to proliferate and only begin to succumb to the drug
effects after 3 days.
It is generally thought that lack of p53 function attenuates apoptosis (289,332). An evaluation of
the extent of apoptosis by annexin V/PI staining demonstrated that H460wt cells exposed to
different doses of cisplatin underwent a much more pronounced degree of apoptosis/necrosis than
H460crp53 cells (Figure 3.1B). This did not appear to be a consequence of differential DNA
damage since cisplatin promoted equivalent DNA damage in the H460p53 wt and H460crp53
cells, based on γH2AX staining performed over a 24 h time period (Figure 3.1C-D).
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Figure 3.1. Cisplatin sensitivity in H460wt cells and H460crp53 cells.
A. Cell viability. Cells were treated with cisplatin (10 μM) for 24 h, washed free of drug,
incubated with fresh medium and stained with trypan blue (n=3). B. Apoptosis Dose Response.
Cells were treated with cisplatin at the indicated doses for 24 h and apoptosis was assessed by
Annexin V-FITC staining. Apoptosis was measured 24 h after cisplatin removal (n=3). C-D.
DNA Damage. Temporal assessment of DNA damage in response to cisplatin. Extent of DNA
damage was measured utilizing flow cytometry to quantify γH2AX staining in cells treated with
cisplatin (10 µM). (D) Representative images of flow cytometry data and (E) quantification of
fluorescence was graphed (n=3). Unless stated, otherwise data were from three independent
experiments, *p < 0.05, cisplatin treated H460wt group vs cisplatin treated H460crp53 group. #p
< 0.05 cisplatin treated group vs untreated control group in each cell line.
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3.3.2. Cisplatin-induced autophagy in p53 wt and p53 knockout cells
Cytoprotective autophagy is generally considered to be a mechanism to ameliorate or evade
apoptosis; hence, we assessed the capacity of cisplatin to promote autophagy in both cell lines.
Figure 3.2A presents images of acridine orange staining of autophagic vacuoles, a rough but
generally accurate indication of the extent of autophagy. Assessment of acidic vesicle formation
by flow cytometry indicated that the extent of autophagy induced by cisplatin was similar in the
two cell lines (Figure 3.2B). To further compare the extent of autophagy and whether cisplatininduced autophagy is going to completion, degradation of p62/SQSTM1 was evaluated by
western blotting. Figure 3.2C (and quantification of the band densities in Figure 3.2D) indicates
that autophagic flux is clearly occurring in both cell lines. Moreover, both H460wt and
H460crp53 cells demonstrate co-localization of LC3 and the lysosomal marker, LAMP-2, when
exposed to cisplatin indicative of autophagic flux (Figure 3.2E). Consistent with the previous
studies in radiation, untreated H460crp53 exhibited greater LC3/LAMP2 co-localization when
compared to H460wt cells, suggesting basal autophagy was higher in H460crp53 cells. These
studies indicate that autophagy appears to be induced to a similar extent in cisplatin-treated H460
cell, regardless of the status of p53, although the process is slightly more rapid in the H460crp53
cells.
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Figure 3.2. Cisplatin induces autophagy in H460wt cells and H460crp53 cells.
A-E.Cells were treated with cisplatin at the indicated doses for 24 h (day 0), after which cells
were washed and incubated in fresh medium. A. Acridine orange staining was performed after
exposure to 10 μM cisplatin. Cells were treated with cisplatin for 24 h (day 0) and stained 48 h
post-drug removal (day 3, n=3). B. Quantification of acridine orange staining. Autophagy
induction was quantified by flow cytometry in response to increasing concentration of cisplatin
2 days after drug exposure (n=3). C. Western blotting. Levels of p62 were determined by
western blotting at the indicated times after 10 µM cisplatin exposure for 24 h (D0). Lysates were
collected on indicated days. One of three representative experiments is shown (n=3). D. Western
blot Densitometry. The bar graph in each panel indicates the relative band intensity generated
from densitometric scans of two independent experiments in arbitrary densitometric units (n=3).
E. Co-localization of LC3 and LAMP. Fluorescence microscopy showing LC3 and LAMP2 colocalization in response to 10 µM cisplatin exposure 2 days after cisplatin removal. (20X
objective, n=2) Unless stated, otherwise data were from three independent experiments, *p <
0.05, cisplatin treated group vs untreated control group in each cell line.
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3.3.3. Evidence for cytoprotective autophagy in the p53 knock-out cells and nonprotective
autophagy in the p53 wild-type H460 cells
Next, the nature of the autophagy was evaluated based on sensitization or lack of sensitization
when autophagy was inhibited using the pharmacological autophagy inhibitors, CQ or 3-MA. Both
H460 cell lines were pre-treated with CQ (10 μM) or 3-MA (1 mM) for 3 h followed by exposure
to 10 μM cisplatin for 24 h. Autophagy was measured after 2 days of incubation with fresh
medium. The increase in LC3-II puncta formation in the presence of CQ (due to inhibition of
autolysosome formation and accumulation of autophagosomes) and decrease in LC3-II puncta
with 3-MA (due to interference with autophagosome formation) indicated that CQ and 3-MA
inhibited cisplatin-induced autophagy (Figure 3.3A). Interference with p62/SQSTM1 degradation
further confirmed that CQ and 3-MA inhibited cisplatin-induced autophagy (Figure 3.3B).
Temporal response studies were then performed to determine the impact of autophagy inhibition
on sensitivity to cisplatin. Figures 3.3D and 3.3E-F show that administration of CQ and 3-MA
increased cell death and apoptosis in response to cisplatin in the H460crp53 cells but failed to
influence cisplatin-induced cell death and apoptosis in the H460wt cells (Figure 3.3C and 3.3EF), indicating that autophagy was cytoprotective in function in the H460crp53 cells but
nonprotective in the H460wt cells.
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Figure 3.3. Pharmacological autophagy inhibition sensitizes H460crp53 cells, but not H460wt
cells to cisplatin exposure.
A. Inhibition of autophagy by CQ and 3-MA. Fluorescence microscopy showing increased
LC3 puncta following CQ (10 µM) co-treatment with 10 µM cisplatin, and decreased LC3 puncta
following 3-MA (1 mM) co-treatment with 10 µM cisplatin. Cells were pretreated with CQ (10
µM) and 3-MA (1 mM) followed by an additional 24 h with cisplatin. Images were taken 48 h
after cisplatin removal. Nuclei were stained with Hoechst 33342 and vacuoles with LC3 antibody
(20x objective, n=2). B. Inhibition of autophagy by CQ and 3-MA. Western blot showing
autophagy blockade by CQ (10 µM) and 3-MA (1 mM) based on levels of p62/SQSTM1 (n=3).
The bar graph in each panel indicates the relative band intensity generated from densitometric
scans of two independent experiments in arbitrary densitometric units. C and D. Influence of
autophagy inhibition on cisplatin sensitivity. Viability of H460wt cells and H460crp53 cells
was monitored based on trypan blue exclusion at indicated days following 10 µM cisplatin
exposure in combination with CQ (10 µM) or 3-MA (1 mM) (n=3). E-F. Influence of autophagy
inhibition on cisplatin induced apoptosis. Annexin V-PI staining showing influence of CQ (10
µM) and 3-MA (1 mM) on apoptosis of H460 cells exposed to cisplatin (10 µM). Cells were
pretreated with CQ or 3-MA for 3 h followed by co-treatment with cisplatin for 24 h. Apoptosis
was measured 24 h after cisplatin removal (n=3). Unless stated otherwise, data were from three
independent experiments, *p<0.05, cisplatin versus cisplatin + CQ (3-MA).
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To confirm the findings generated using pharmacological inhibition, short hairpin RNA (shRNA)
was used to knockdown Atg5, an autophagy regulatory gene, in both H460 cell lines. Figure 3.4A
verifies the status of Atg5 by Western blotting in the two cell lines. The decrease in LC3 puncta
(Figure 3.4B) indicates that shAtg5 effectively inhibited autophagy in both H460 cell lines.
Inhibition of autophagy was confirmed by interference with cisplatin-induced degradation of
p62/SQSTM1 (Figure 3.4C). Here, genetic interfere with autophagy yielded a similar outcome
to that observed with the pharmacological autophagy inhibitors; specifically, autophagy inhibition
failed to alter growth inhibition and apoptosis in response to cisplatin in H460wt cells (Figures
3.4D and 3.4E-F), but increased cell growth inhibition and apoptosis in the H460crp53 cells
(Figures 3.4D and 3.4E-F).

Taken together, these data demonstrate that in the H460wt cells the autophagy is nonprotective
since there is no further sensitization with autophagy inhibition and no increase in apoptosis. In
contrast, autophagy “switches” to the cytoprotective form/function when p53 is knocked out, as
autophagy inhibition increases sensitivity to cisplatin and results in enhanced apoptosis in the
H460crp53 cells.
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Figure 3.4. Influence of genetic autophagy inhibition on cisplatin sensitivity in H460wt cells
and H460crp53 cells.
A. Western blot showing the silencing of Atg5 in H460wt cells and H460crp53 cells. B and C.
Autophagy inhibition by Atg5 silencing. The bar graph in each panel indicates the relative band
intensity generated from densitometric scans of three independent experiments in arbitrary
densitometric units (n=3). B. Fluorescence microscopy showing decreased LC3 puncta following
treatment with 10 µM cisplatin in shAtg5 H460 cells. Images were taken 48 h after cisplatin
removal. Nuclei were stained with Hoechst 33324 (20x objective, n=2). C. Western blot showing
autophagy blockade by Atg5 knockdown based on levels of p62/SQSTM1. Proteins were collected
48 h after cisplatin removal (n=2). The bar graph in each panel indicates the relative band intensity
generated from densitometric scans of two independent experiments in arbitrary densitometric
units. D. Influence of autophagy inhibition on cisplatin sensitivity. Viability of H460wt cells
and H460crp53 cells was monitored based on trypan blue exclusion at indicated days following
cisplatin exposure in shATG5 in H460wt cells and H460crp53 cells (n=3). E. Influence of
autophagy inhibition on cisplatin induced apoptosis. Annexin V-PI staining showing apoptosis
in H460 cells exposed to cisplatin (10 µM) with and without ATG5 silencing. Apoptosis was
measured 24 h after cisplatin removal. (n=3). Unless stated otherwise, data were from three
independent experiments, *p < 0.05, shControl + cisplatin versus shAtg5 + cisplatin, #p < 0.05,
shControl versus shATG5.
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3.3.4. Cisplatin induced senescence in H460wt and H460crp53 NSCLC cells
Autophagy and senescence often occur in parallel in response to cytotoxic therapy. Given that
senescence contributed to the differential sensitivity to radiotherapy in our previous studies (142);
therefore, we investigated the role of senescence induction and its contributions to the differential
sensitivity seen between H460wt and H460crp53 cells. Cells were exposed to 10 µM cisplatin and
senescence-associated ß-galactosidase (SA-ß-gal) activity was assayed. Figure 3.5A demonstrates
ß-galactosidase staining (blue) was increased in both H460wt and H460crp53 cells. SA-ß-gal
activity was also monitored by flow cytometry for a more quantitative approach. Temporal
analysis of SA-ß-gal activity was increased in both cell lines in response to cisplatin exposure,
indicating senescence was induced to similar extents in both the H460wt and H460crp53 NSCLC
cells (Figure 3.5B).
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Figure 3.5. Cisplatin induced senescence in H460wt and H460crp53 NSCLC cells.
A. β-galactosidase staining and cell morphology. β-galactosidase staining indicating the
induction of senescence by cisplatin (10 µM) in both cell lines (scale bar = 20 μm). B.
Quantification of senescence. C12FDG staining and flow cytometry to quantify the extent of
senescence in H460wt and H460crp53 cells. Cisplatin induced senescence in both H460wt and
H460crp53 cells. Unless stated, otherwise data were from three independent experiments. n.s.
H460wt versus H460crp53 cells.
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3.3.5. Inhibition of cytoprotective autophagy shifts the temporal response to cisplatin in the
H460crp53 cells
Given that senescence was induced to similar extents in both cell lines, we wanted to confirm the
differential sensitivity to cisplatin exhibited between the two cells lines was partly due to
differences in autophagic function. To examine the contributions of cytoprotective autophagy to
cisplatin sensitivity, we compared the temporal responses shown in Fig. 3.3C and 3.3D with and
without pharmacological autophagy inhibition by replotting these time courses in Figures 3.6A
and 3.6B. The blockade of cytoprotective autophagy in H460crp53 cells exposed to cisplatin
resulted in a temporal decline in cell viability that was essentially identical to that in the cisplatin
treated H460 p53wt cells. In agreement with these observations, Figure 3.6C demonstrates a
similar relationship when cell viability data from Fig. 3.4D is plotted together to show an overlap
of the decline in cell viability in response to cisplatin when autophagy has been genetically
inhibited in H460crp53 cells when compared to H460wt shControl cells exposed to cisplatin.
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Figure 3.6. Inhibition of cytoprotective autophagy shifts the temporal response to cisplatin
in the H460crp53 cells.
A-C. Influence of autophagy inhibition on cisplatin sensitivity in p53 wt and p53 KO cells.
Cell viability data from figure 3C and 3D were overlaid to compare the functional role of
autophagy in H460crp53 and H460wt cells using the pharmacological inhibitors, CQ (A) and
3MA (B). C. Cell viability data from figure 4D were overlaid to compare the functional role of
autophagy on cisplatin sensitivity via genetic silencing of ATG5. *p<0.05 p53wt shControl + cis
vs. crp53 shATG5 + cis, n.s. p53wt + cis vs. crp53 + cis + CQ (3-MA or shAtg5).
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Figure 3.7. Cellular responses to cisplatin exposure in H460wt and H460crp53 NSCLC cells.
In response to cisplatin exposure, H460wt cells were significantly more sensitive than H460crp53
cells. H460wt cells underwent greater apoptosis induction compared to H460crp53 cells; however,
the extent of autophagy induction and senescence induction was similar in the two cell lines.
Autophagy inhibition revealed H460wt cells underwent nonprotective autophagy, while
H460crp53 cells induced cytoprotective autophagy. These data demonstrated nonprotective
autophagy induced in p53wt non-small cell lung cancer cells in response to cisplatin can be
“switched” to protective autophagy in isogenic crp53 cells, and that inhibition of cytoprotective
autophagy is sufficient to restore cisplatin sensitivity in the crp53 cells, through the promotion of
apoptosis. Created with BioRender.com.
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3.4 Discussion
Autophagy is one mechanism thought to be induced by cancer cells to evade apoptosis (333).
Cisplatin exposure resulted in autophagy induction to a similar extent in both the H460wt and
H460crp53 cells. Autophagy inhibition (by pharmacological and genetic interventions) increased
cisplatin-induced cell death and apoptosis in H460crp53 cells (i.e., evidence of cytoprotective
autophagy) but did not alter either outcome in the p53 wt H460 cells (i.e. evidence of
nonprotective autophagy). As a result, the temporal decline in cell viability in the H460crp53
cells when autophagy was inhibited essentially paralleled that observed in p53 wt H460 cells,
suggesting cytoprotective autophagy was contributing to the differential sensitivity and differing
extent of apoptosis observed between the two cell lines when exposed to cisplatin. Consequently,
these findings support the premise that cytoprotective autophagy can confer a relative degree of
resistance to chemotherapy.
This work further interrogates the relative contributions of p53 status and autophagy to sensitivity
and resistance to chemotherapy. Tasdemir et al and colleagues had reported that inhibition of
cytoplasmic p53 led to autophagy in enucleated cells and conversely that cytoplasmic p53 was
able to repress the enhanced autophagy of p53 null cells, providing evidence of a relationship
between p53 and autophagy (170). Topotecan, a topoisomerase I inhibitor, induced cytoprotective
autophagy in p53wt colon cancer cells in vitro and in vivo, but induced cytotoxic autophagy in
p53 null colon cancer cells (334). Tripathi et al. demonstrated that cisplatin induced protective
autophagy in p53 knockdown embryonal carcinoma cells, which would be consistent with the
findings presented in this work (169). However, Maycotte et al reported on nonprotective
autophagy in p53 null 4T1 breast tumor cells exposed to cisplatin (298). These differential
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outcomes indicate that it cannot be predicted, a priori, the nature that drug or radiation-induced
autophagy will exhibit, based solely on the status of p53 in the cells.

The Autophagic Switch. Collectively, autophagy can play various functional roles in response to
chemotherapy and radiation; moreover, the mechanism(s) determining the functional form induced
in response to therapy still remains unclear. To add further complexity to these observations, a
unique phenomenon whereby autophagy can “switch” between functions has also been
demonstrated (141,142,326). For instance, the “autophagic switch” was also exhibited in studies
of estrogen receptor (ER) expression in breast cancer cells exposed to gemcitabine (335).
Gemcitabine induced cytoprotective autophagy in ER- BCap37 breast cancer cells, but cytotoxic
autophagy in ER+ Bcap37 cells. Further, genetic silencing of the ERa receptor in the ER+ Bcap37
cells was sufficient to switch the cytotoxic form of autophagy to the cytoprotective form. In an
osteosarcoma model, drug-resistant cells exhibited cytoprotective autophagy, with greater reliance
on autophagy for metabolic maintenance, whereas, drug-sensitive cells exhibited cytotoxic
autophagy in response to camptothecin (336).

The studies presented with cisplatin and

radiotherapy in the same set of isogenic H460 NSCLC cell lines provide further evidence of the
existence of an “autophagic switch” in tumor cells in response to anti-cancer therapy.
In the current work, cisplatin induced similar levels of autophagy in both p53 wt and H460crp53
cells, indicating that the capacity to undergo cisplatin-induced autophagy is essentially p53independent. However, as in many of the studies cited above, the nature of the autophagy changed
in association with the different p53 statuses of the two cell lines. Inhibition of autophagy
increased drug sensitivity and apoptosis in the H460crp53 cell to similar extents as p53wt cells
exposed to cisplatin. This critical observation from the current work suggests that cells lacking
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functional p53 are capable of undergoing apoptosis to the same degree as p53 wild-type cells.
As was shown in Figure 3.6, autophagy inhibition in H460crp53 cells shifted the temporal
response to cisplatin to be virtually identical to that in the H460wt cells, suggesting that
cytoprotective autophagy and not p53 function was largely responsible for the reduced sensitivity
to cisplatin of the crp53 cells (Figure 3.7).
Interestingly, this differs from our recent findings in studies involving ionizing radiation, where
radiation sensitivity appeared to be a function primarily of the extent of senescence and appeared
to be largely unrelated to autophagy (337) (Table 3.1). In these studies, the same set of isogenic
cell lines, H460wt and H460crp53 cells, exhibited nonprotective autophagy in both cells when
exposed to radiation and autophagy inhibition failed to alter radiation sensitivity or radiationinduced apoptosis in either cell line. However, through these studies, we demonstrate that crp53
cells have the capacity to undergo nonprotective autophagy (in the case of radiation), and this
response is “switched” to protective autophagy in the case of cisplatin treatment (Table 3.1).
Collectively, these studies suggest the existence of an autophagic switch, not only between
isogenic cell lines differing in p53 status but also depending on the therapeutic agent utilized.

While these studies with H460wt and H460crp53 cells isogenic cell lines exposed to radiation or
chemotherapy demonstrated functional switches in autophagy, both in terms of cytotoxic agent
and p53 status, very little is understood as to the mechanisms regulating autophagic function. DNA
damage is the primary mechanism through which both radiation and cisplatin exert their antitumor
effects. Furthermore, autophagy is induced in response to both anti-cancer treatments and aids in
the turnover of proteins involved in DDR and cell cycle checkpoints (296). Below we consider
whether the extent and/or temporal profile of DNA damage may contribute to the differential
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functions of autophagy induced in response to cisplatin and radiation in H460wt versus H460crp53
cells. The extent of DNA damage was similar in both cell lines when exposed to radiation or
cisplatin; however, there were differences in the temporal profile of DNA damage incurred
between the two treatment modalities (Figure 3.8). Radiotherapy induced maximal DNA damage
around 30 mins-1 h post-IR exposure which seemed to resolve to basal levels within 24 h post-IR;
in contrast, cisplatin demonstrated a delayed and much lower extent of DNA damage, but one that
did not exhibit resolution in the timeframe monitored (Figure 3.8).
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Figure 3.8. Radiation and Cisplatin induced DNA damage in H460wt and H460crp53 cells.
A. Radiation-induced DNA damage. Cells were exposed to 6 Gy radiation and DNA damage
was measured by 𝛾-H2AX staining. Fluorescence of 𝛾-H2AX was quantified using flow
cytometry. B. Cisplatin-induced DNA damage. Cells were exposed to 10M of cisplatin for 24
h and DNA damage was measured by 𝛾-H2AX staining throughout the 24 h exposure time.
Fluorescence of 𝛾-H2AX was quantified using flow cytometry.
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A potential factor contributing to resistance to therapy is that in tumor cells with higher basal
autophagy, autophagy may facilitate the removal of therapy-induced damage more efficiently.
Studies by Liang et al. examining the role of autophagy in multidrug-resistant ovarian carcinoma
observed that radiation induced relatively low levels of apoptosis; inhibition of apoptosis with
ZVAD did not significantly alter survival or cell death, confirming that apoptosis is not the primary
therapeutic response to radiation, at least in this experimental model (126). These studies also
demonstrated higher basal autophagy in the multidrug-resistant phenotype SKVCR cells compared
to human SKOV3 ovarian carcinoma cells, suggestive of a cytoprotective function. Moreover,
inhibition of autophagy with 3-MA sensitized the multidrug-resistant cells to radiation while
having only modest effects on the parental SKOV3 cells. Similarly, when examining LC3/LAMP2
colocalization in untreated control cells in figures 2.3D and 3.2E, H460crp53 cells exhibit greater
LC3 fluorescence compared to H460wt NSCLC cells, allowing initial indications that basal
autophagy may be higher in H460crp53 cells compared to H460wt cells. While further
examination is required, this difference in basal autophagy may play a role in the differences in
autophagic function exhibited between the two cell lines in response to cisplatin. The lower and
more delayed extent of DNA damage in response to cisplatin exposure may allow H460crp53,
with higher basal autophagy, to maintain sufficient clearance of cisplatin-induced damage,
sustaining cells below critical cell death thresholds.
Inhibition of cytoprotective autophagy in the H460crp53 cells in response to cisplatin restored
apoptosis induction and cisplatin sensitivity to similar extents as H460wt cells, where the
autophagy was nonprotective, suggesting the crosstalk between autophagy and apoptosis may play
a key role (73). One possibility is that autophagy may sequester and remove damaged mitochondria
through mitophagy, preventing cytochrome C release and activation of intrinsic death pathways
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(338). Another potential mechanism through which autophagy modulates apoptosis is through
selective cargo shuttling and degradation of pro-apoptotic proteins. Autophagy can mediate the
degradation of caspase 8 and evade caspase 8-mediated cell death; furthermore, deficiencies in
autophagy can also result in caspase 8 dimerization on the membrane of the autophagosome and
promote TRAIL-mediated cell death (339,340). Similarly, Wang et al. demonstrated NOXA, a
BH3-only member of the Bcl2 family that promotes apoptosis, is targeted by p62 for autophagic
degradation, reducing apoptotic induction in NSCLC and colorectal cancer cell lines (341).
Autophagy inhibition increased NOXA protein accumulation, suppressed tumor growth, and
activated cell death pathways (341). Thus, if autophagy was cytoprotective in nature due to its
capabilities of trafficking pro-apoptotic proteins, then it could be hypothesized that autophagy
inhibition would relieve this sequestration and switch responses to a pro-apoptotic cell fate. Future
studies focusing on in-depth analysis of autophagic cargo may provide promising insights on the
role of specific cargo on the nature of autophagic function and maybe a potential rationale for why
one functional form of autophagy “switches” to another as exhibited in the H460crp53 cells.

Taken together, these studies provide proof of concept that cytoprotective autophagy can confer
intrinsic resistance to chemotherapy, based on a comparison of cisplatin sensitivity in two
isogenic cell lines where autophagy demonstrated cytoprotective and nonprotective functions.
However, it is necessary to recognize that autophagy induced by chemotherapy or radiation may
not always be cytoprotective in the clinic and the therapeutic benefit of autophagy inhibition may
only be successful in scenarios where the autophagy is cytoprotective. These studies further
provide an additional model of the “autophagic switch” in cancer therapy using a set of isogenic
cell lines, but the mechanistic basis for the autophagic switch still remains to be determined.
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While these studies with cisplatin indicate p53 status may influence autophagic function,
collectively taking the findings of both the radiation and cisplatin studies as a whole suggest that
it cannot be predicted whether therapy-induced autophagy will be protective or nonprotective
based solely on functional p53 status. If autophagy inhibition is to be incorporated into therapeutic
intervention, it will likely be necessary to identify the functional form(s) of autophagy for each
therapeutic intervention in a particular patient (i.e. personalized medicine), reiterating the
importance of screening prior to the inclusion of autophagic inhibitors to clinical regimens (285).

Table 3.1. Tumor responses to radiation and cisplatin exposure in H460wt and
H460crp53 NSCLC cells.
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Chapter Four: What are the contributions of nonprotective autophagy
to senescence?
4.1 Introduction
Autophagy and senescence are both activated in response to radiotherapy and chemotherapy, often
concomitantly in tumor cells exposed to anti-cancer therapy as shown in the studies presented
within this dissertation (142,342). Given the coexistence of autophagy and senescence in response
to therapy and overlapping mechanistic triggers, it is necessary to gain further insights into the
relationship between the two processes.
Initiation of autophagy and senescence can be achieved through a number of cellular stress
regulators, including p53, ROS, and mTOR (134,168,280,300,343,344) (Figure 4.1). Therapyinduced damage activates p53, an essential tumor suppressor and stress sensor that can modulate
the activity of both senescence and autophagy. p53 regulates a vast number of cellular processes,
including by not limited to apoptosis, autophagy, and senescence. p53 mediates the transcription
of a number of cell cycle inhibitors, including p21waf1 and p16, which inhibit the interaction
between cyclins and cyclin-dependent kinases and induce cell cycle arrest (345). Luo et al.
demonstrated that p53 activation using Nutlin-3a radiosensitized H1299 (p53 null) cells by
activating p53-p21waf1 pathways and inducing cellular senescence (232). Furthermore, depending
on the cellular localization of p53, nuclear p53 can activate autophagy through the transcriptional
regulation of key ATG proteins or directly stimulate autophagy through DRAM (346). In contrast,
cytoplasmic p53 mediates an inhibitory effect on autophagy through ubiquitin-mediated beclin1
degradation and inhibition of AMPK (169,170). Another common meditator of both autophagy
and senescence is oxidative stress. Anti-cancer therapies, such as radiation and cisplatin, can result
in increased ROS levels due to mitochondrial dysfunction and uncoupling, as well as genotoxic
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stress. Autophagy serves to alleviate the cellular burden of the damaged proteins and mitochondria
and to remove stressors, such as damaged mitochondrial DNA (mtDNA), which may stimulate
senescence induction (347–349). While autophagy is induced in response to oxidative stress,
prolonged autophagy impairment in the presence of oxidative stress can result in senescence
induction (343,350). Furthermore, excessive ROS accumulation can further exacerbate DNA
damage, resulting in p53/p21Cip1 activation and promotion of senescence (227,319,351,352).
Taken together, pathways activated in response to therapy-induced damage can regulate both
autophagy and senescence.
Additionally, mTOR is an important regulator of both senescence and autophagy. mTOR prevents
activation of autophagy initialization; thus, mTOR inhibition has been shown to upregulate
autophagy (134,353). Studies by Nam et al demonstrated autophagy activation in response to
mTOR inhibition in glioma, lung, colorectal, and breast cancer cell lines when exposed to
radiotherapy; furthermore, mTOR blockade (which promotes autophagy) resulted in premature
senescence and restoration of radiosensitivity (354). Seminal work by Narita et al. showed that
mTOR and autophagic machinery may be important in SASP processing during senescence
(178,355). The authors observed a specialized compartment, which they termed the TORautophagy spatial coupling compartment (TSACC), where products of cellular catabolic processes,
such as autophagic degradation could feed into cellular anabolic processes, to promote protein
synthesis. Disruption of mTOR localization to TSACC was shown to inhibit interleukin-6/8
synthesis in Ras-induced senescence, suggesting that autophagy may play a role in SASP
generation, which can reinforce the senescent phenotype.
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A plethora of anticancer therapies and concomitant stress pathways activate both autophagy and
senescence as alternative cell fates in response to genotoxic and oxidative stress induced by
clinically relevant doses of anti-cancer agents; however, whether autophagy and senescence are
interdependent still remains elusive and further inquiry is necessary. Given that both autophagy
and senescence are currently being examined as attractive means for tumor sensitization to therapy,
it is important to understand the relationship between the two processes in order to gauge which
pathway could be manipulated to provide a more favorable therapeutic outcome. In these studies,
we delved deeper into the role of autophagy in senescence maintenance and recovery from the
growth-arrested phenotype in HCT116 cells exposed to radiotherapy. One intrinsic limitation in
studies aiming to address the relationship between autophagy and senescence is that in the case of
cytoprotective autophagy, autophagy inhibition results in apoptosis, as exemplified both in the
literature and studies within this dissertation (142,211); consequently, it becomes difficult to
distinguish whether the exhibited responses are due to the impact of autophagy inhibition on cell
killing or direct effects of autophagy inhibition on senescence. In an effort to circumvent this
limitation, these studies examined the effects of nonprotective autophagy on senescence induction
and recovery from the senescent phenotype, since by definition blockade of nonprotective
autophagy does not alter sensitivity or apoptotic cell death to anti-cancer therapy.
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Figure 4.1. Interconnectivity of cellular senescent and autophagic pathways.
Given that both autophagy and senescence are two pathways activated by cellular stress and
damage, it is plausible and well-exhibited in pre-clinical models that the two processes often occur
in parallel in response to chemotherapy and radiation. Both autophagy and senescence converge
on several molecular signaling pathways and share multiple regulators, such as p53, mTOR, and
ROS. DNA damage induced by genotoxic therapies, such as etoposide, cisplatin, or radiotherapy,
is recognized by ATM and results in its subsequent phosphorylation. Phosphorylated ATM
activates DDR pathways, as well as initiates signaling cascades for p53 phosphorylation and
activation. Activated p53 regulates a number of responses, including p21 induction resulting in
cellular growth arrest and senescence, as well as transcription of proapoptotic proteins.
Furthermore, subcellular localization of p53 can also modulate autophagy. Nuclear p53 and
DRAM/p53 signaling axis leads to increased transcription of autophagic machinery; whereas
cytoplasmic p53 can block autophagy induction and promote apoptosis and growth arrest.
Anticancer therapies increasing intracellular ROS levels and inducing mitochondrial dysfunction
can result in upregulation of mitophagy. Clearance of dysfunctional and aged mitochondria can
prevent senescence, which occurs due to damage accumulation and oxidative stress. Moreover,
elevated ROS levels can exacerbate DNA damage activating cellular growth arrest and apoptotic
pathways. Lastly, autophagy may contribute to the senescent phenotype through the processing of
SASP factors, such as IL-6 and IL-8, via a specialized compartment, TASCC, in which products
from the cells catabolic autophagic processes provide raw materials for the anabolic protein
synthesis processes. Collectively, while both autophagy and senescence are induced in parallel in
response to anti-cancer therapeutics, whether the two processes are interdependent still remains
elusive and requires further inquiry. Created with BioRender.com.
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4.2. Methods

4.2.1. Cell Culture and Treatment
HCT116 were generously provided by Dr. Sarah Spiegel, at Virginia Commonwealth University.
HCT116 cells were cultured in RPMI both supplemented with 10% (v/v) fetal bovine serum
(Thermo Scientific, SH30066.03), 100 U/mL penicillin G sodium (Invitrogen, 15140–122), and
100 μg/mL streptomycin sulfate (Invitrogen, 15140–122). Cells were maintained at 37 °C under a
humidified, 5% CO2 atmosphere at sub-confluent densities.
The ATG5-knockdown was generated as follows: Mission shRNA bacterial stocks for ATG5
were purchased from Sigma Aldrich. Lentiviruses were produced in HEK 293T cells cotransfected using EndoFectinTM Lenti Transfection Reagent (GeneCopoeia, 1001-01) with a
packaging mixture of psPAX2 and pMD2.G constructs (Addgene). Media containing the viruses
was used to infect the HCT116 cells; puromycin (1 μg/ml) was used as a selection marker to
enrich for the infected cells.

Cells were seeded on day 0 followed by irradiation (0,2,4,6, 8 or 10 Gy) on day 1 utilizing a 137Cs
irradiator. Media was replenished every other day. For autophagy inhibition studies, cells were
treated with pre-treated with CQ (0 or 10 µM) 3 h prior to IR (0 or 4 Gy) exposure. All assays
performed as previously described.
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4.3.Results
4.3.1. Radiation induced senescence and autophagy in HCT116 cells
Cells were exposed to varying doses of radiation, media was replenished, and cells were stained
with either X-gal or C12FDG to monitor senescence induction or acridine orange to monitor
autophagy induction 72 h post-IR. Figures 4.2A-B show the collateral, parallel and dosedependent induction of autophagy and senescence by ionizing radiation in the HCT116 tumor cell
lines.
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Figure 4.2. The induction of senescence and autophagy in HCT116 cells in response to
radiation.
A. SA-β-galactosidase staining of HCT116 cells treated with 4 Gy radiation demonstrating
induction of senescence (20x objective). Fluorescence was quantified using flow cytometry 72 h
post-irradiation. B. Fluorescent microscopy images of acridine orange staining 48 hours postradiation (4 Gy). Increased acidic vesicle formation is visualized (20x objective). Fluorescence
was quantified using flow cytometry 72 h post-irradiation (n=2). Results presented were from three
independent experiments, unless otherwise indicated.
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4.3.2. Radiation induced nonprotective autophagy in HCT116 colorectal cells
Autophagy was pharmacologically inhibited using CQ to assess the impact of autophagy inhibition
on senescence induction and recovery. Specifically, HCT116 cells were pretreated with CQ (5
µM) for 3 hours before being irradiated and then maintained in culture medium for an additional
24 hours. Failure of lysosomal acidification in cells treated with CQ was demonstrated through the
yellow staining of autophagic vacuoles (Figure 4.3A). Moreover, inhibition of autophagy was
confirmed via western blot analysis demonstrating accumulation of the p62 protein levels with
prior CQ exposure. (Figure 4.3B). Pharmacological inhibition of autophagy by CQ did not alter
the sensitivity of HCT116 cells to radiation and did not promote radiation-induced growth arrest
(Figures 4.3C). Autophagy inhibition also failed to alter radiation-induced apoptosis (Figure
4.3D). Collectively, autophagy exhibited a nonprotective function HCT116 colorectal cells in
response to radiotherapy; furthermore, these data are consistent with the previous studies with
H460 NSCLC cells in which nonprotective autophagy was induced in response to radiation in this
experimental model.
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Figure 4.3. Radiation induced nonprotective autophagy in HCT116 colorectal cells.
A-E. Cells were pre-treated with CQ (5 µM) 3 h prior to radiation (4 Gy) exposure. Media was
replenished 24 h post-treatment. A. Acridine orange staining indicating blockade of lysosomal
fusion in cells pre-treated with CQ (20x objective). B. Western blot analysis demonstrating
autophagy blockade via p62 accumulation in cells pre-treated with CQ (n=2). C. Cells were treated
with 4 Gy radiation alone or with CQ pre-treatment, and viable cell number was assessed via trypan
blue exclusion on the indicated days. D. Annexin 5/PI staining was used to assess apoptosis 48 h
post-radiation [radiation (4 Gy) alone or with CQ (5 µM) pre-treatment]. Autophagy blockade did
not alter radiation-induced apoptosis (n = 2). Results presented were from three independent
experiments, unless otherwise indicated. n.s. compared to radiation alone.
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4.3.3. Senescence induction and recovery from growth arrest was independent of autophagy
in HCT116 cells exposed to radiation
As shown in Figure 4.4A-B, senescence induced by radiation in the HCT116 cells was not affected
by autophagy inhibition. Figures 4.4C shows that HCT116 cells underwent growth arrest followed
by proliferative recovery upon exposure to radiation, where HCT116 cells proliferative recovery
was evident 3 days after radiation exposure. Furthermore, growth arrest and proliferative recovery
profiles were virtually identical in HCT116 cells with and without pharmacological autophagy
inhibition.
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Figure 4.4. Pharmacological autophagy inhibition did not alter senescence induction or
recovery in HCT116 cells exposed to radiation.
A. SA-β-galactosidase staining demonstrating increased SA-β-galactosidase activity in both cells
exposed to radiation alone or pre-treated with CQ prior to radiation. B. SA-β-galactosidase activity
was monitored by measuring C12FDG staining using flow cytometry. C. Cell viability data from
figure 2D. The expanded scale for the lower portion of the graph is shown to visualize proliferative
recovery from senescent growth arrest. Results presented were from three independent
experiments, unless otherwise indicated. n.s. compared to radiation alone.
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Finally, short hairpin RNA was utilized to knockdown ATG5 to assess the effect of genetic
autophagy inhibition (silencing of ATG5, Figure 5A) on senescence induction and maintenance.
In agreement with the pharmacological inhiation data, genetic interference of autophagy did not
influence radiation sensitivity or proliferative recovery (Figure 5B-C).

While the data is not shown in this dissertation, these studies were also performed with H460 (p53
wt) NSCLC cells and 4T1 (p53 null) breast cancer cells exposed to etoposide and doxorubicin,
respectively (251). Consistent with the HCT116 studies, doxorubicin and etoposide exposure
induced both senescence and autophagy in H460 NSCLC and 4T1 breast cancer cells; moreover,
both of these DNA-damaging chemotherapies induced nonprotective autophagy. Pharmacological
and genetic autophagy interference did not alter senescence induction or proliferative recovery
from the senescent state. Collectively, H460 NSCLC cells, 4T1 breast cancer cells, and HCT116
colorectal cells exhibited nonprotective autophagy in response to etoposide, doxorubicin, and
radiation, respectively. Further, nonprotective autophagy did not significantly contribute to
senescence initiation or maintenance (Figure 6).
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Figure 4.5. Genetic autophagy inhibition did not alter senescence induction or recovery in
HCT116 cells exposed to radiation.
A. Western blot demonstrating ATG5 knockdown. B-C. Viable cell number was assessed in shControl and
shATG5 HCT116 cells exposed to 4 Gy radiation. Representative curves of three independent studies are
shown (n = 3). Results presented were from three independent experiments, unless otherwise indicated. n.s.
compared to radiation alone.
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4.4. Discussion

While autophagy and senescence often occur concomitantly in response to chemotherapy and
radiotherapy, very little is understood on whether these two processes are interdependent. These
studies, utilizing multiple cytotoxic therapies and multiple cell lines, demonstrated senescence
induction and proliferative recovery are independent of autophagy when the autophagy is
“nonprotective” in function (251). Furthermore, we observed that autophagy inhibition did not
alter the extent of senescence induction or recovery in HCT116 colorectal carcinoma cells exposed
to 4 Gy radiation. In these studies, at least in the scenario of nonprotective autophagy where
senescence is the predominant response, it is feasible to speculate that while autophagy may be
induced in a “conventional” effort to maintain survival, the senescence response predominates in
conferring a survival advantage to the cells. Whether autophagy contributes to the senescent
phenotype or is a relic of senescence is not fully understood; however, these studies indicate that
at least in scenarios where the autophagy is nonprotective, senescence induction and recovery is
not reliant on autophagy. Alternatively, Vijayaraghavan et al. examined the effects of autophagy
inhibition in breast cancer cells exposed to hormonal therapy in combination with CDK 4/6
inhibitors (356). These authors demonstrated that autophagy inhibition significantly reduced cell
viability and tumor burden of breast tumors exposed to Palbociclib, as well as the combination of
Palbociclib and letrozole, suggesting that autophagy was cytoprotective in function. Furthermore,
this sensitization resulting from the administration of an autophagy inhibitor in combination with
Palbociclib was mediated through the synergistic induction of senescence. However, the studies
by Vijayaraghavan et al. suggest autophagy and senescence may share an inverse relationship,
complicating the association between the two processes as well as those originally proposed by
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Young et al. in which blockade of autophagy was shown to suppress senescence in a model of
oncogene-induced senescence (357,358).
Building on the previously established literature that autophagy may be a component for the
maintenance of the senescent phenotype, autophagy inhibitors have been proposed as potential
agents to clear senescent cells. Was et al. demonstrated exposure to BafA1 in doxorubicin-induced
senescent HCT116 cells reduced cell viability and delayed tumor cell repopulation in the shortterm; however, in the long run, single pulse BafA1 exposure resulted in re-activation of autophagy
and increased proliferation in the HCT116 recovering subpopulation in vitro and increased tumorburden in vivo when compared to chemotherapy alone (359). Therefore, while autophagy
inhibitors may be an alluring therapeutic for the clearance of senescent cells, further studies
elucidating the nature behind the contributions of autophagy to the senescent phenotype are
necessary. In another closely related study, Vera-Ramirez et al. showed autophagy inhibition with
HCQ decreased survival of dormant breast cancer cells and reduced lung metastasis; however,
HCQ administration was minimally effective once dormant cells had regained proliferative
capacity, suggesting the role of autophagy in sustaining tumor dormancy in breast cancer cells
(360). While the extent of senescence was not assessed in these studies, senescence may a potential
tumor dormancy model and further studies are warranted interrogating the contributions of
autophagy in senescence-associated tumor dormancy and recovery (209). Alternatively, aberrant
activation of autophagy may serve as a potential senolytic. Studies by Wakita et al. demonstrated
that administration of a BET inhibitor, ARV825, cleared oncogene-induced senescent cells, as well
as doxorubicin-induced senescent HCT116 colorectal cells in vitro and in vivo (361). Furthermore,
the authors showed the senolytic capabilities of ARV825 were partially mediated through
autophagy modulation. Genetic and pharmacological blockade of autophagy compromised
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ARV825-induced senolysis, indicating autophagy was necessary for senescent cell clearance by
the BET inhibitor (361).

The tumor suppressor gene, TP53, coding for p53, regulates cellular mechanisms modulating both
autophagy and senescence, as well as various other cell fates. Whether p53 is important in toggling
cellular responses between senescence and autophagy is not well understood; however, our studies,
albeit indirectly, provide some insights on the role of p53 status on autophagy and senescence
induction. H460 NSCLC cells and HCT116 colorectal cells, expressing wild type p53, and 4T1
breast cancer cells, which are null in p53 status, underwent senescence and autophagy to similar
extents in response to etoposide, radiation, and doxorubicin, respectively. Regardless of p53 status
and therapeutic exposure, all three cell lines underwent nonprotective autophagy; this concurs with
our earlier conclusion that while p53 status may influence the function of autophagy, the specific
function induced is inconsistent. Along the same lines of investigation, Sui et al. examined the
effect of p53 status on autophagy and senescence induction in HCT116 under serum-starved
conditions (362). Under serum starvation, HCT116 p53+/+ cells exhibited significantly greater
autophagic flux than HCT116 p53-/- colorectal cells and protected p53 wild-type cells from
starvation-induced cell death. Moreover, HCT116 p53+/+ cells underwent autophagy and
quiescence in response to serum starvation, while HCT116 p53-/- cells induced senescence to a
greater extent than p53 wild-type cells (362). Autophagy inhibition in HCT116 p53+/+ cells
demonstrated cytoprotective autophagy in response to serum starvation, as expected, and increased
ß-gal staining, indicating inhibition of cytoprotective autophagy enhanced senescence induction in
HCT116 p53+/+ cells. However, autophagy inhibition did not alter senescence induction in
HCT116 p53-/- cell (362). Collectively, these studies reiterate the ability of tumor cells to toggle

116

between cellular responses, the inconsistency of p53 status as a predictive marker for senescence
induction and autophagy function, as well as the complexity underlying the relationship between
autophagy and senescence.

Summary The premise that autophagy confers resistance to various treatment modalities has been
the basis for ongoing clinical trials combining chemotherapy or radiation; however, there are a
number of conceptual and experimental reservations relating to these clinical trial strategies. One
is that, as we and others have shown in multiple publications, autophagy is not uniformly
cytoprotective, often exhibiting cytotoxic and non-protective functions. In scenarios where
autophagy inhibition may be beneficial (i.e., when autophagy is cytoprotective in function), from
a directly clinical perspective, it is highly uncertain whether chloroquine and hydroxychloroquine
can achieve levels in the circulation and the tumor to sufficiently inhibit autophagy to the extent
necessary for radiosensitization or chemosensitization. Finally, if and when more efficacious
autophagy inhibitors are identified, it is necessary to acknowledge that autophagy also provides
homeostatic regulation in normal tissues such as the central nervous system, and therefore
autophagy inhibition might represent a double-edged sword that would induce unanticipated and
undesirable (intolerable) toxicities.

While autophagy plays a role in initial sensitivity to radiation and chemotherapy in tumor cells,
accumulating literature has supported the induction of a prolonged growth arrest, characteristic of
senescence, as a response to radiation and chemotherapy. Furthermore, a subset of these senescent
cells is capable of regaining proliferative capacity, a possible contributor to tumor dormancy and
disease recurrence. Consequently, senescent growth arrest may provide a significant contribution
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to chemotherapy and radiation resistance and disease reemergence. Though the implications of
senescence cannot be truly resolved due to a lack of effective inhibitors of senescence induction,
senolytics may provide a novel class of therapeutics to add to the arsenal of cancer chemotherapy
in attempts to eliminate senescent cancer cells. Moreover, given the fact that autophagy and
senescence often occur in tandem, it is also important to gain insights as to the predominant
responses activated to evade cell death in response to the respective anti-cancer regiment in order
to determine whether incorporation of either an autophagy inhibitor or a senolytic with antineoplastic therapy may provide a more favorable means to eliminate residual tumor cells.

Disclosure: The work presented in this dissertation has been previously published in
Radiation Research (190(5):538-557, Nov 2018; 194(2):103-115, Aug 2020), Biochemical
Pharmacology (175:113896, May 2020), International Journal of Medicine (21(4):1427, Feb
2020; 21(23), Nov 2020), and Advances in Cancer Research (2021).
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